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The vesicular monoamine transporter-2 (VMAT2) packages monoamines into synaptic vesicles 
in the central nervous system.  Not only vital for monoaminergic neurotransmission, VMAT2 
protects neurons from cytosolic dopamine-related toxicity by sequestering dopamine into 
vesicles.  This dissertation research is focused on determining the basic mechanisms of VMAT2 
degradation—an unexplored aspect of VMAT2 regulation.  The processes of protein synthesis 
and degradation balance to maintain proteostasis.  As VMAT2 availability and function directly 
impact monoamine neurotransmission, its degradation is an important aspect of VMAT2 
maintenance to study.  While it has been proposed that VMAT2 is degraded by the lysosome, an 
acidic membrane-bound organelle, there is no direct evidence demonstrating this.  In a PC12 cell 
model system stably expressing VMAT2-GFP, pharmacological tools were used to determine the 
impact of inhibiting pieces of cellular degradation machinery (the lysosome or the 26S 
proteasome) on VMAT2.  Both mature and immature forms of VMAT2 accumulated following 
inhibition of the proteasome, but not the lysosome.  In addition, at least a portion of the 
accumulated VMAT2 following proteasomal inhibition appears to be K48-linked 
polyubiquitinated—a post-translational modification associated with proteasomal degradation.  
Immature VMAT2 also accumulated following inhibition of endoplasmic reticulum-associated 
degradation (ERAD), a proteasome-dependent quality control mechanism for misfolded or 
damaged proteins undergoing processing in the ER.  Demonstrated with immunocytochemistry 
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and confocal imaging, the proportion of VMAT2 overlapping with an ER marker increased 
following proteasomal inhibition.  These results indicate that immature VMAT2 is likely subject 
to ERAD as it undergoes processing in the ER.  Unexpectedly, mature VMAT2 accumulated 
following proteasomal, but not lysosomal inhibition.  While this result could be due to secondary 
effects of proteasomal inhibition or changes in VMAT2 synthesis, it is also possible that mature 
VMAT2 can be degraded by the proteasome.  This would be a unique finding, as glycosylated, 
transmembrane proteins, such as VMAT2, must overcome a large energy barrier for 
retrotranslocation from a membrane.  As these experiments were done under basal conditions, 
the results don’t exclude a role for lysosomal degradation under other circumstances.  For 
example, there may be multiple pathways of VMAT2 degradation:  proteasomal-dependent 
under basal conditions and lysosomal-dependent under conditions of synaptic activity. 
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1.0  INTRODUCTION 
The goal of this project was to identify the basic mechanisms of vesicular monoamine 
transporter-2 degradation (VMAT2), a protein that has a vital role in monoaminergic signaling.  
Despite this importance, little is known regarding the regulation of VMAT2.  Its degradation was 
chosen to investigate because the regulation of VMAT2 expression levels is crucial to normal 
dopamine transmission and disease states involving alterations in the dopamine system. In 
addition, to date, nothing has been published concerning this topic—an important part of 
proteostasis.  Research regarding VMAT2 degradation not only provides information about 
VMAT2 regulation, but also may provide insight into the degradation of synaptic vesicular 
proteins in general.  This dissertation project was broken into two specific aims: (1) to 
investigate what cellular machinery is involved in VMAT2 degradation and (2) to investigate the 
role of parkin, an E3 ligase, in VMAT2 degradation. 
1.1 MONOAMINERGIC SIGNALING 
Monoamine neurotransmitters are involved in a multitude of functions within the central nervous 
system.  Classified because of their structure, the group includes neurotransmitters such as 
histamine, serotonin, epinephrine, norepinephrine and dopamine.  These compounds are 
considered neuromodulators, sometimes modulating the direct effects or release of other 
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neurotransmitters (Pennartz et al., 1992, Harvey and Lacey, 1997, Guzman et al., 2003, 
Tecuapetla et al., 2009, Tritsch and Sabatini, 2012).  As opposed to the classical 
neurotransmitters such as glutamate and GABA, neuromodulators act on metabotropic receptors, 
sometimes located extrasynaptically (Sesack et al., 1994, Yung et al., 1995, Beaulieu and 
Gainetdinov, 2011).  The release of neuromodulators can be phasic (display firing bursts, driven 
by action potentials), like release of classic neurotransmitters (Grace and Bunney, 1984a).  In 
addition, release, especially of dopamine, can also be tonic, meaning small amounts can be 
released independent of action potential in a slow, irregular pattern (Grace and Bunney, 1984b, 
Floresco et al., 2003). 
While relatively small groups of neurons in the central nervous system synthesize 
different monoamines, they have wide-reaching processes that impact a number of processes 
throughout the brain.  For example, the raphe nuclei are a cluster of nuclei in the midbrain that 
synthesize serotonin (Törk, 1990).  Modestly sized, these nuclei have projections throughout the 
brain, impacting cognition, circadian rhythms, memory, and emotion—to name just a few (Puig 
and Gulledge, 2011, Versteeg et al., 2015, Zhang and Stackman, 2015, Bocchio et al., 2016).  As 
a whole, monoamines influence almost every aspect of brain function in some way.  Although 
there are several monoamines in the central nervous system, each with their own circuitry, this 
thesis work will be focusing on dopamine. 
1.1.1 The dopamine system and molecular components 
One of the most studied monoamines is dopamine (DA).  The dopaminergic system is involved 
in a variety of systems such as movement, reward circuitry, and cognition.  Dysfunction within 
the dopaminergic system is implicated in several diseases and disorders, including schizophrenia, 
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attention-deficit/hyperactivity disorder, Parkinson’s disease, and addiction.  Despite the 
involvement of DA in several circuits and systems, there are only a few locations in the brain 
that contain dopaminergic cell bodies.  The most understood of these areas are located in the 
midbrain—the substantia nigra (SN) and ventral tegmental area (VTA).  Neurons from these 
areas project to many areas of the brain, but here I will focus on a few main pathways and their 
primary roles.  Dopaminergic neurons in the SN pars compacta project to the dorsal striatum to 
form the nigrostriatal pathway, which is primarily involved in control of movement (Haber et al., 
2000).  This group of neurons is notorious for their degeneration in Parkinson’s disease, resulting 
in the motor symptoms typical of the disease.  Dopaminergic neurons in the VTA, also located in 
the midbrain, project to a number of brain areas, including the amygdala and hippocampus.  A 
group of neurons project from the VTA to the cortex (primarily the prefrontal cortex), forming 
the mesocortical pathway, which seems to play a role in cognition and motivation (Ungerstedt, 
1971, Haber, 2014).  Another group of neurons project from the VTA to the nucleus accumbens 
(Groenewegen et al., 1999).  This pathway is heavily involved in the reward circuitry, and its 
role in the biological basis of addiction is often studied (Salamone, 1994, Sutton and Beninger, 
1999, Baldo and Kelley, 2007).  The roles these circuits play in brain functions are simplified 
here; more likely each circuit is involved in several functions and there is not a clear division of 
function between them (Verheij and Cools, 2008, Wise, 2009). 
There are several molecular components/proteins that are essential for dopaminergic 
homeostasis.  In addition to DA receptors, other components are involved in the synthesis, 
packaging, release, re-uptake, and degradation of DA.  The synthesis of DA is regulated mainly 
by tyrosine hydroxylase (TH)—the rate-limiting step in the conversion of tyrosine to L-DOPA 
(Nagatsu et al., 1964a, b).  Aromatic L-amino acid decarboxylase (AADC) then converts L-
 4 
DOPA into DA (Lovenberg et al., 1962).  If the necessary enzymes are located in the neuron, 
DA can then be used to synthesize epinephrine and norepinephrine—previously mentioned 
monoaminergic neurotransmitters (Levin et al., 1960, Connett and Kirshner, 1970).  DA is then 
packaged into vesicles for exocytosis by the vesicular monoamine transporter (VMAT).  
Following release, DA is taken back up into the presynaptic neurons via the dopamine 
transporter (DAT) located at the plasma membrane.  DA can then be degraded (or re-packaged 
into vesicles) by catechol-O-methyl transferase (COMT) or monoamine oxidase (MAO) 
(Lachman et al., 1996, Edmondson et al., 2004).  Dopamine receptors are metabotropic and can 
be divided into two families—D1-like (D1 and D5) or D2-like (D2, D3, D4) receptors.  While all 
DA receptors are G-protein coupled, the ultimate result of being ‘excitatory’ or ‘inhibitory’ to 
the post-synaptic neuron depends on which receptor is activated (Stoof and Kebabian, 1981, 
Clark and White, 1987, Seeman and Van Tol, 1994, Beaulieu and Gainetdinov, 2011).  
Additionally, some D2 receptors are located on the presynaptic neuron and function as 
autoreceptors, regulating DA release from that neuron (Usiello et al., 2000). 
1.2 THE VESICULAR MONOAMINE TRANSPORTER-2 
The vesicular monoamine transporter (VMAT) is responsible for transporting dopamine into 
vesicles, readying them for exocytosis.  As the name suggests, VMATs transport not only DA, 
but all monoamines.  Although the existence of a monoamine transporter in synaptic vesicles had 
been known for decades, the VMAT cDNA wasn’t cloned until the early 1990’s (Erickson et al., 
1992, Liu et al., 1992, Surratt et al., 1993, Takahashi and Uhl, 1997).  There emerged two 
isoforms of the transporter, previously identified as CGAT (chromaffin granule amine 
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transporter) and SVAT (synaptic vesicular amine transporter).  CGAT would become known as 
VMAT1, the isoform encoded by the SLC18A1 gene, while SVAT would become known as 
VMAT2, encoded by the SLC18A2 gene.  
  VMAT belongs to the MFS (Major Facilitator Superfamily) family of transporters and 
the SLC (solute carrier family of transporters) subfamily.  The transporters included in this 
subfamily display little sequence homology with each other and are grouped based on function.  
The vesicular acetylcholine transporter (VAChT) shares the greatest sequence homology with 
VMAT, although the vesicular glutamate transporters (VGLUTs) also share some similarities—
namely, basic structure and function.  It was once thought that the roles of the vesicular 
transporters were very structured—VMATs transport monoamines, VGLUTs transport 
glutamate, and so on.  However, there is some evidence that a small subset of dopaminergic 
neurons also co-release GABA in a VMAT-dependent manner, although this requires further 
confirmation (Tritsch et al., 2012).  Glutamate is also released from a small subpopulation of 
dopaminergic neurons, but this is dependent on the VGLUT and not VMAT (Sulzer et al., 1998, 
Tecuapetla et al., 2010).   
 No crystallized structure of VMAT exists, although based on hydrophobicity plots, it is 
predicted to have 12 transmembrane domains.  Both VMAT1 and VMAT2 have cytoplasmic N 
and C-termini and a large loop facing the interior of the vesicle.  This large loop contains 3-4 
residues capable of N-glycosylation.  Figure 1 is the sequence and predicted transmembrane 
domains of human VMAT2, indicating putative N-glycosylation sites (adapted from various 
sources, namely Robert Edwards’ group) (Erickson et al., 1992, Peter et al., 1996, Takahashi and 
Uhl, 1997, Hoffman et al., 1998).  In addition to any role in folding or structural stability, these 
glycosylation sites are thought to be involved in sorting or trafficking (discussed in section 
 6 
1.2.1), although knockdown of all VMAT1 glycosylation sites reduced vesicular uptake by 50% 
without altering gross cellular localization (Yelin et al., 1998, Yao and Hersh, 2007). 
 
 
Figure 1.  Human VMAT2 sequence and putative transmembrane domains.  The amino acid human VMAT2 
sequence from the N-terminus starting at the left.  Putative N-glycosylation sites are represented by branches in the 
large, intravesicular loop.  A sequence contained in the C-terminus that’s involved in VMAT2 endocytosis, 
KEEKMAIL, is indicated in red. 
1.2.1 Expression and localization 
While the underlying function and protein structure of VMAT1 and VMAT2 are similar, there 
exist differences between these two transporter molecules.  One of these differences is 
expression—VMAT1 is only located in the periphery, while VMAT2 exists in both the periphery 
and central nervous system.  According to immunohistochemical studies performed with human 
tissue by Erickson et al. 1996, VMAT1 is primarily localized to chromaffin cells in the adrenal 
medulla and enterochromaffin cells of the small and large intestines.  In the periphery, VMAT2 
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is also expressed in chromaffin cells in the adrenal medulla—the only location where VMAT1 
and VMAT2 coexist.  VMAT2 has been identified in enterochromaffin-like cells in the stomach 
and endocrine pancreatic cells (Erickson et al., 1996).  Similar patterns of system-wide 
localization are seen in rats, although VMAT1 is more predominately expressed in chromaffin 
cells of the adrenal medulla; a smaller subset of these cells also contain VMAT2 (Peter et al., 
1995).  VMAT2 is expressed in both rat and human peripheral sympathetic ganglia.  In contrast, 
VMAT1 is expressed in some human, but not rat, peripheral sympathetic ganglia.   
VMAT2, but not VMAT1 is expressed in the central nervous system.  VMAT2 can 
essentially be found in all brain regions that contain monoaminergic cell bodies or terminals.  
Nirenberg and colleagues used electron microscopic immunocytochemistry to view cellular 
localization of VMAT2 in the rat SN and VTA.  They found VMAT2 was largely localized to 
tubulovesicular structures in the cell body, but also to the Golgi apparatus and endoplasmic 
reticulum.  These tubulovesicular organelles are a proposed site of somatodendritic dopaminergic 
release (Hattori et al., 1979, Nirenberg et al., 1996).  VMAT2 was rarely observed at the plasma 
membrane, in either cell bodies or axons (Nirenberg et al., 1996).  Although frequently located 
on synaptic vesicles (SVs), VMAT2 is also found on dense core vesicles (DCVs).  DCVs are 
distinct from SVs and typically contain peptides or hormones, instead of the classic 
neurotransmitters in SVs (like glutamate or GABA).  Furthermore, DCVs and SVs have different 
biogenesis pathways and exocytosis mechanisms (Kelly, 1993).  
Studies of VMAT2 trafficking to DCVs or SVs have largely been performed in 
neuroendocrine cell lines or PC12 cells, as they contain a larger proportion of DCVs (also called 
large dense core vesicles, LDCVs, or large dense core granules).  In these cells, VMAT is 
preferentially localized to LDCVs instead of the smaller vesicles analogous to the SVs in the 
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brain (Liu et al., 1994).  Both glycosylation and residues in the C-terminal have been implicated 
in trafficking to LDCVs (Varoqui and Erickson, 1998, Krantz et al., 2000, Li et al., 2005, Yao 
and Hersh, 2007).  Specifically, phosphorylation of acidic residues located at the C terminus 
interferes with VMAT2 localization to LDCVs (Waites et al., 2001).  It is unclear if these 
processes are retained in central nervous system neurons, where a much larger proportion of SVs 
exist.   
1.2.2 Pharmacological properties 
The primary function of the VMATs is to sequester monoamines into vesicles for exocytosis.  
VMAT does this by taking advantage of a proton gradient maintained by V-type ATPases.  
VMAT2 relies on this proton gradient and membrane potential to fully function.  It is generally 
accepted that VMATs transport two protons out of the vesicle for every one monoamine 
molecule into the vesicle (Knoth et al., 1981).  Recently, a “hinge” model has been proposed as a 
mechanism of transport.  Yaffe and colleagues suggest that two 6 transmembrane helices contain 
several critical residues that act as “hinge points” to open and close the two helices, allowing for 
translocation of substrates (Yaffe et al., 2013). 
 While this basic mechanism is assumed to be true for both VMAT1 and VMAT2, the 
two forms differ somewhat in substrate affinity.  The successful isolation and cloning of VMAT 
cDNAs has allowed for direct testing of VMAT1 and VMAT2 pharmacological properties.  
VMAT1 and VMAT2 have similar affinities for serotonin, dopamine, epinephrine, and 
norepinephrine, although VMAT2 has 2-4 times greater affinity for all of these substrates than 
VMAT1 (Peter et al., 1994, Erickson et al., 1996).  VMAT2 displays a much higher affinity for 
histamine than VMAT1 (Ki in the mid to high micromolar range), suggesting histamine is 
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unlikely to be a typical substrate of VMAT1 (Peter et al., 1994, Merickel and Edwards, 1995, 
Erickson et al., 1996).  Interestingly, there exists only approximately 60% homology between the 
human VMAT1 and human VMAT2 amino acid sequences, perhaps accounting for these 
differences in substrate affinity (Erickson et al., 1996, Wang et al., 1997).  As shown in Figure 2, 
the transmembrane domains are the most conserved, while there exists sequence divergence in 
the N-terminus, the large intravesicular loop, and the C-terminus.  In contrast, the VMAT2 
amino acid sequence appears to be fairly well-conserved across mammalian species.  As seen in 
Figure 3, there exists approximately 90% homology between rat, mouse, and human VMAT2, 
suggesting VMAT2 maintains similar pharmacological features across mammalian species. 
Several inhibitors of the VMATs have been identified.  Perhaps the most well studied 
inhibitor of VMAT1 and VMAT2 is reserpine.  Selective and potent, reserpine is an irreversible, 
competitive inhibitor with a KD in the low nanomolar range (Scherman and Henry, 1984, 
Erickson et al., 1996).  Interestingly, reserpine and histamine poorly displace one another, 
suggesting the substrate binding site for histamine differs (at least partially) from other 
monoamine substrates (Merickel and Edwards, 1995).  Another compound that inhibits VMAT is 
lobeline, which is a nonspecific, noncompetitive inhibitor with an IC50 in the low micromolar 
range (Teng et al., 1997, Teng et al., 1998).  Finally, tetrabenazine (TBZ) is a reversible inhibitor 
of VMAT2, but not VMAT1.  While VMAT2 has an IC50 for TBZ in the mid nanomolar range, 
concentrations up to 10 µM don’t fully block VMAT1 activity (Pettibone et al., 1984, Peter et 
al., 1994, Erickson et al., 1996).   Radiolabeled TBZ binding studies have been used to assess 
VMAT2 levels in vitro, as well as in vivo with PET (positron emission tomography), as TBZ is a 
relatively short-lived, noncompetitive inhibitor (Scherman and Henry, 1984, DaSilva and 
Kilbourn, 1992, DaSilva et al., 1994, Vander Borght et al., 1995). 
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Figure 2.  Sequence alignment of human VMAT2 and VMAT1.  Predicted transmembrane domains are indicated by 
a line above hVMAT2.  Asterisks located below hVMAT1 indicate residue homology.  Note the greatest sequence 
divergence in the N- and C-termini, as well as the large intravesicular loop following the first transmembrane 
domain.  
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Figure 3.  Sequence alignment of human, mouse, and rat VMAT2.  Predicted transmembrane domains are indicated 
by a line above hVMAT2.  Asterisks located below rVMAT2 indicate residue homology. 
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1.2.3 Role in determining quantal size 
There’s significant evidence indicating VMAT levels have the ability to confer quantal size, or 
the amount of monoamine packaged into a vesicle and released during a quantal event.  While 
the number of VMATs within a vesicle remains somewhat unknown, there’s indication that this 
number is a factor in determining how much monoamine is within a vesicle.  A number of 
studies have been done in David Sulzer’s lab utilizing PC12 cells, a rat pheochromocytoma cell 
line that contain vesicles and are capable of monoaminergic release.  They demonstrate with 
amperometry that manipulation of VMAT2 levels alters the quantal size without altering the 
number of vesicles undergoing exocytosis (Pothos et al., 2000).  A separate group obtained 
similar results, finding that L-DOPA (the dopamine precursor) and reserpine enhanced and 
diminished, respectively, vesicular volume and quantal size (Colliver et al., 2000).   
 Further evidence (albeit more indirect) that VMAT2 regulates quantal size is obtained 
from VMAT2 knockdown and over-expression animal models.  Homozygous VMAT2 knockout 
mice do not have long-term viability and perish within a few days of birth (Takahashi et al., 
1997, Wang et al., 1997).  Heterozygous knockout mice have 50% of wild-type VMAT2 levels 
with a corresponding decrease in striatal DA and evoked DA release in primary neuronal 
cultures, indicating released DA is proportional to VMAT2 levels (Fon et al., 1997, Takahashi et 
al., 1997).  A genetic line of mice expressing only about 5% VMAT2 have a similar 90-95% 
reduction in brain monoamine levels, including striatal DA (Colebrooke et al., 2006, Taylor et 
al., 2009).  Recently, Gary Miller’s group has begun to characterize a mouse model of VMAT2 
over-expression.  These mice express about 3 times more VMAT2 than wild-type mice and have 
increased striatal DA content.  VMAT2 over-expression mice also have greater evoked DA 
release in striatal slices and interestingly, increased vesicle size (as measured using electron 
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microscopy) (Lohr et al., 2014).  Together, these data strongly support the notion that VMAT2 
levels can impact quantal size in vivo.  Despite this data, it remains unclear what compensatory 
mechanisms take place when VMAT2 is genetically manipulated.  There is some indication that 
post-synaptic dopamine receptors in heterozygous knockout mice are more sensitive than in 
wild-type mice, as heterozygous knockout mice have enhanced responses to apomorphine, a DA 
receptor agonist (Wang et al., 1997). 
1.2.4 Role in neuroprotection 
The primary role of VMAT is to transport monoamines into vesicles.  Because some 
monoamines (notably, dopamine) can be harmful to the cell when remaining in the cytosol, 
VMAT also plays a role in neuroprotection.  Free DA has the ability to auto-oxidize, forming 
DA quinones and reactive oxygen species (Graham, 1978).  The metabolism of DA by 
monoamine oxidase (MAO) also creates a potentially harmful substance, H2O2, which can then 
form hydroxyl radicals.  These products of DA metabolism can contribute to the overall level of 
oxidative stress within a neuron, making it more vulnerable to insults and subsequent 
neurotoxicity (Hastings et al., 1996, Linert et al., 1996, LaVoie and Hastings, 1999, Mosharov et 
al., 2009, Segura-Aguilar et al., 2014).  Because of this, it is especially important to sequester 
DA into vesicles, where it won’t be metabolized by MAO or auto-oxidized.  In fact, there’s 
evidence that TH and VMAT2 directly interact and are coupled with AADC (Cartier et al., 
2010).  In this way, levels of cytoplasmic DA are limited following synthesis.  High levels of 
cytoplasmic DA are thought to play a role in neuronal cell death seen in Parkinson’s disease, in 
addition to neurotoxicity induced by some psychostimulants (Cadet and Brannock, 1998, Sulzer 
and Zecca, 2000, Goldstein et al., 2014).   
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 There are several lines of evidence indicating that VMAT2 over-expression or 
knockdown/inhibition affects vulnerability to toxic insult.  For example, an in vitro study has 
demonstrated that over-expression of VMAT2 in PC12 cells protected against L-DOPA-induced 
toxicity, while reserpine treatment potentiated L-DOPA toxicity (Weingarten and Zhou, 2001).  
Presumably these effects are due to more or less VMAT2 being available to sequester the 
increased DA levels caused by L-DOPA treatment.  Similarly, primary dopaminergic neurons 
derived from VMAT2 heterozygous knockout mice are also more vulnerable to L-DOPA toxicity 
(Kariya et al., 2005b).  However, another group didn’t observe the same, perhaps due to use of a 
different L-DOPA treatment paradigm (Reveron et al., 2002).  VMAT2 inhibition has also been 
shown to increase vulnerability to BH4-induced toxicity (Choi et al., 2005).  BH4 is a cofactor 
for tyrosine hydroxylase that can contribute to oxidative stress by undergoing auto-oxidation and 
generating toxic by-products that then increase formation of DA quinones. (Choi et al., 2000, 
Choi et al., 2003).  It’s proposed that an overall reduction in VMAT2 DA storage capability then 
potentiates an increase of BH4-mediated DA quinone production.   
 There are additional lines of evidence from in vivo studies that VMAT2 levels can affect 
oxidative stress-related toxicity.   VMAT2 heterozygous knockout mice are more susceptible to 
dopaminergic cell death in paradigms of MPP+/MPTP neurotoxicity—a pharmacological model 
of Parkinson’s disease (Takahashi et al., 1997, Gainetdinov et al., 1998).  Likewise, mice 
expressing lower VMAT2 levels also exhibit greater toxicity induced by high doses of 
methamphetamine (Fumagalli et al., 1999, Larsen et al., 2002, Guillot et al., 2008).  Mice over-
expressing VMAT2 are protected against terminal and cell loss due to neurotoxic doses of MPP+ 
and methamphetamine, supporting this hypothesis (Lohr et al., 2014, Lohr et al., 2015).    
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 In work done in Drosophila by David Krantz’s group, loss of function VMAT mutants 
are more susceptible to rotenone and paraquat-induced neurotoxicity (pesticide models of 
Parkinson’s disease).  VMAT over-expression was partially protective against dopaminergic cell 
loss induced by rotenone, but not paraquat.  The different results obtained between the two 
compounds are not understood, although it may be due to differences in mechanisms of action 
(Lawal et al., 2010).  In a different model of Parkinson’s disease, expression of mutant parkin in 
Drosophila can cause motor dysfunction and dopaminergic cell death.  The effects are 
exacerbated by VMAT knockdown and ameliorated by VMAT over-expression (Sang et al., 
2007).  Again, it is unclear why VMAT impacts mutant parkin-mediated dopaminergic cell loss, 
although it is presumed cytosolic DA plays a role. 
 The ability of VMAT2 to modulate vulnerability to toxic compounds, such as MPP+, 
rotenone, or methamphetamine, could be due to a number of mechanisms.  It is possible that 
altered VMAT2 levels impact neuronal vulnerability because the aforementioned compounds (a) 
are substrates of VMAT2, and more/less VMAT2 sequesters them, preventing/exacerbating their 
toxic actions (b) are inhibitors of VMAT2 function, either directly or by interfering with 
vesicular pH gradient or (c) alter cytoplasmic DA without impacting VMAT2 directly, but 
VMAT2 levels then modulate free DA levels, which could then in turn affect oxidative stress.  In 
fact, several of the aforementioned toxic compounds influence VMAT2 activity directly.  MPP+ 
is believed to re-distribute dopamine from vesicles to the cytoplasm, increasing free DA; it is 
hypothesized that MPP+ may do so by acting as a VMAT substrate (Daniels and Reinhard, 1988, 
Lotharius and O'Malley, 2000).  Methamphetamine, a psychostimulant, is thought to do the 
same.  Several research groups, notably David Sulzer’s, have proposed and provided evidence 
for the “weak base hypothesis”—methamphetamine and amphetamine act as weak bases that 
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disrupt the vesicular pH gradient and re-distribute DA from the vesicle to the cytoplasm, 
contributing to levels of cytosolic DA and ultimately, oxidative stress and terminal loss (Maron 
et al., 1983, Sulzer and Rayport, 1990, Cubells et al., 1994, Pifl et al., 1995, Sulzer et al., 1995, 
Mundorf et al., 1999, Freyberg et al., 2016).  Finally, it has been suggested that one of rotenone’s 
actions is as a VMAT2 inhibitor, also resulting in accumulation of cytosolic DA (Sai et al., 2008, 
Watabe and Nakaki, 2008).  This would explain the differential effects VMAT2 over-expression 
has on rotenone and paraquat, as it is unclear if paraquat has a similar effect on VMAT2. 
 The contribution of VMAT2 to dopaminergic neuron vulnerability is such that some have 
proposed mice expressing very low (approximately 5% of wild-type) VMAT2 can be used as a 
model for Parkinson’s disease (PD).  Gary Miller’s group has done extensive work with these 
mice, termed “VMAT2 LO” mice.  VMAT2 LO mice display deficits that follow a degenerative 
pattern, sometimes not becoming apparent until later in life—12-18 months.  These mice display 
deficits in motor function reminiscent of PD, accompanied by increased indications of oxidative 
stress and a reduction in striatal dopaminergic neurons (Caudle et al., 2007).  They also develop 
earlier signs of non-motor PD symptoms.  At around 5 months old, VMAT2 LO mice have 
deficits in olfactory discrimination tests.  Even earlier, at around 2 months, they have abnormal 
gastric emptying and circadian activity (Taylor et al., 2009).  Even though PD is rarely diagnosed 
prior to the display of motor symptoms, it is now thought that deficits in olfaction and digestion 
precede these symptoms, highlighting the potential usefulness of VMAT2 LO mice as an animal 
model of Parkinson’s disease.  
While these data don’t provide direct evidence that VMAT2 has an inherent 
neuroprotective role by sequestering dopamine, the implication is very apparent. How VMAT2 
modulates dopamine-induced oxidative stress is an ongoing area of research.  Furthermore, much 
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of these data point to the importance of VMAT2 and implicate it in the etiology of diseases and 
disorders that affect monoamines, especially Parkinson’s disease. 
1.2.5 Involvement in diseases and disorders 
Because of the critical role VMAT2 has in monoaminergic signaling, attention has been paid to 
its potential role in human diseases and disorders.  Investigations have focused mainly on two 
approaches:  genetic analysis and evaluation of VMAT2 levels, often involving in vivo ligand 
binding studies.  Dysfunction of the DA and serotonin systems has been implicated in a wide 
range of disorders, ranging from the psychiatric to the neurodegenerative.   
 As already hinted at, there is interest in investigating the potential involvement of 
VMAT2 in PD etiology.  The selective vulnerability of monoaminergic neurons to degeneration 
in this disease has implicated VMAT2—a protein common to all monoaminergic neurons.  The 
contribution of cytosolic dopamine-mediated oxidative stress to this selectivity also implicates 
VMAT2.  It has been suggested that the ratio of dopamine transporter to VMAT2 can impact cell 
vulnerability in PD—both proteins are key regulators of cytoplasmic dopamine levels (Miller et 
al., 1999, Gonzalez-Hernandez et al., 2004).  For instance, the ratio of DAT to VMAT2 in the 
putamen is greater than in the caudate, two areas of the striatum.  Indeed the putamen has greater 
cell loss in PD (Miller et al., 1999).  Reduced striatal VMAT2 levels and SN mRNA levels have 
been reported in post-mortem brains of PD patients (Harrington et al., 1996, Miller et al., 1999). 
VMAT2 is expressed in platelets, and these mRNA levels are also reduced in PD patients, 
although not correlated with disease severity, age, or treatment status (Zucker et al., 2001b, Sala 
et al., 2010).  Corroborating evidence is obtained from PET imaging using radiolabeled DTBZ 
(dihydrotetrabenazine).  PD patients have a lower number of DTBZ binding sites in striatum and 
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SN, presumably due to reduced VMAT2 levels (Lee et al., 2000, Bohnen et al., 2006).  
Interestingly, VMAT2 levels (as assessed both post-mortem and in vivo) are reduced when 
accounting for dopaminergic terminal loss; there is less VMAT2 in the surviving neurons and 
terminals.  Furthermore, isolated vesicles from post-mortem PD patients have decreased VMAT2 
uptake, taking into account binding sites (or VMAT2 levels) (Pifl et al., 2014).  This data 
suggests that the function of VMAT2 itself is impaired in PD—not just that there are reduced 
levels.  Further evidence that VMAT2 may be associated with PD comes from the finding that 
VMAT2 immunoreactivity has been localized to α-synuclein positive Lewy bodies—protein 
aggregates that are a pathological feature of PD (Yamamoto et al., 2006).  
 Despite these findings, it is still unclear if VMAT2 is directly involved in the etiology or 
selective vulnerability of monoaminergic neurons in PD.  It is quite possible that the changes 
seen in VMAT2 are secondary and these changes do not directly affect progression of the 
disease.  In attempt to further differentiate between these possibilities, scientists have looked for 
genetic differences in PD patients.  Results are varied; one research group found polymorphisms 
in the VMAT2 gene associated with increased risk for PD in an Italian population, while another 
group did not find the same in a Japanese population (Kariya et al., 2005a, Brighina et al., 2013).  
It is unclear if any of these polymorphisms have functional consequences; a study using 
numerous variants for in vitro vesicular uptake assays suggests not (Burman et al., 2004).   One 
study found gain-of-function haplotypes that are protective for PD, but only in women (Glatt et 
al., 2006).  The haplotypes found are expected to increase transcriptional activity of VMAT2, 
indicating increased VMAT2 levels may indeed confer protective qualities.  Due to inconsistent 
results from these studies and small effects, the findings should be replicated before any 
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conclusions are drawn about genetic vulnerability to PD from VMAT2 mutations or 
polymorphisms.  
While VMAT2 has been investigated in a variety of other disorders, more extensive 
research has been done in regards to depression, bipolar disorder, and schizophrenia—all of 
which have evidence of dysfunctional monoaminergic signaling.  Monoaminergic, especially 
serotonergic, dysfunction has long thought to be involved in the etiology of major depressive 
disorder and bipolar disorder, so investigation into VMAT2 is a logical avenue to follow.  
Investigation of any potential abnormalities in VMAT2 was also encouraged by the observation 
that VMAT2 heterozygous knockout mice display signs of a depressive phenotype, which are 
reversed by administration of antidepressants (Fukui et al., 2007, Taylor et al., 2009).  VMAT2 
inhibitors also elicit depressive-like symptoms or behavior in both humans and rodents (Preskorn 
et al., 1984, Frank, 2010, Nunes et al., 2013, Randall et al., 2014).  While there is an obvious 
lack of literature concerning VMAT2 levels (obtained either post-mortem or via radiolabeled 
DTBZ binding) in patients with major depressive disorder, there is evidence of increased 
VMAT2 DTBZ binding in patients with bipolar disorder, although the difference compared to 
controls was quite small, possibly due to a low number of subjects (Zubieta et al., 2000, Zubieta 
et al., 2001).  Similar findings were also observed in patients with schizophrenia (Zubieta et al., 
2001, Zucker et al., 2002).  Although confirmation of these results is needed, VMAT2 
haplotypes that occur with increased frequency in patients with schizophrenia and bipolar 
disorder have been identified (Gutierrez et al., 2007).   
It should be noted that genetic or functional changes in VMAT2 alone are unlikely to 
contribute to the entirety of these disorders, as they can be considered spectrum disorders.  That 
is, the presentation of symptoms vary greatly between individuals and etiology is unlikely to be 
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one singular cause.  Furthermore, there is in vitro evidence that selective serotonin reuptake 
inhibitors (common treatments for major depressive disorder) and in vivo evidence that lithium 
(a common bipolar disorder treatment) affect VMAT2 function (Zucker et al., 2001a, Yasumoto 
et al., 2009).   Treatment status should be taken into consideration when assessing data from 
human studies, although a low subject number often proves this difficult. 
To date, there has only been one VMAT2 mutation definitively linked to a disorder.  In 
2013, Rilstone and co-authors described a case study of a Saudi Arabian family who displayed 
Parkinson’s disease-like symptoms and global developmental delays.  Affected family members 
had a homozygous mutation corresponding to a proline to leucine mutation in the VMAT2 387 
amino acid position.  This mutation, located by a transmembrane segment, is thought to have 
severe structural consequences.  Expression of the mutated VMAT2 in cells resulted in greatly 
reduced VMAT2 uptake activity, about 7% of wild-type.  Thought to have autosomal recessive 
inheritance, this is the only identified VMAT2 mutation in the human population to directly 
cause major dysfunction (Rilstone et al., 2013). 
1.2.6 Regulation 
Despite the importance of VMAT2—its critical role in neurotransmission as well as its potential 
involvement in a wide range of diseases—relatively little is know about its regulation on a 
molecular level.  For instance, few studies have examined the role of post-translational 
modifications in VMAT2 activity.  While residues in the VMAT2 C-terminus have been 
demonstrated to be constitutively phosphorylated in heterologous cell models, the purpose of 
these modifications are unclear, as they don’t seem to alter baseline uptake activity (Krantz et al., 
1997).  In another study, phospho-mimetic replacement of two N-terminus residues reduced 
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uptake activity, although it is unclear if phosphorylation at these sites occurs in vivo (Torres and 
Ruoho, 2014).    
There has also been some investigation into protein-protein interactions that regulate 
VMAT2 activity.  Unsurprisingly, several of these efforts have focused on proteins that play a 
role in the etiology of PD.  Mutations in α-synuclein cause familial PD and aggregated α-
synuclein is found in Lewy Bodies, a pathological marker of PD.  α-Synuclein seems to play a 
role in vesicular docking prior to fusion and exocytosis, but may also directly impact VMAT 
(Larsen et al., 2006).  In vitro, over-expression of wild-type and mutant α-synuclein reduced 
VMAT2 expression and uptake activity (Lotharius et al., 2002, Guo et al., 2008).  While these 
results implicate α-synuclein in regulating VMAT2 levels, the exact mechanisms of this are 
unknown.  Furthermore, it is unclear if mutant α-synuclein expressed in PD greatly alters 
VMAT2 function, as both over-expression of mutant and wild-type α-synuclein had essentially 
the same impact on VMAT2; alternatively, mutant α-synuclein could be a gain-of-function 
mutation.  Another protein implicated in PD, DJ-1, has been shown to modulate VMAT2 
activity.  A proportion of DJ-1 is localized to synaptic vesicles, but its function is much less clear 
than α-synuclein’s (Usami et al., 2011).  DJ-1 overexpression increases VMAT2 mRNA, protein 
levels, and uptake activity (Ishikawa et al., 2012, Lev et al., 2013).  Furthermore, DJ-1 appears to 
directly bind to VMAT2, perhaps directly impacting its function independent of transcriptional 
regulation (Ishikawa et al., 2012). 
More extensive work, led by Gudrun Ahnert-Hilger, has been done studying the role of G 
proteins in VMAT regulation.  Expression of the heterotrimeric G protein Gαο2 down-regulates 
VMAT1 and VMAT2 activity in cells and in purified vesicle preparations (Ahnert-Hilger et al., 
1998, Holtje et al., 2000).  Activation of G proteins inhibited VMAT2 uptake activity in 
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platelets, reducing the Vmax but increasing the Km (Holtje et al., 2003).  In this paper, the authors 
also determined that Gαq is responsible for this action in platelets.  Furthermore, this regulation 
appears to depend on vesicular content—regulation did not occur when vesicles were depleted.  
The authors propose that the first VMAT2 intravesicular loops may act as a ‘receptor’, sensing 
vesicular content and mediating this regulatory effect (Brunk et al., 2006).  
It should be noted that most of this work has been done in cells and it’s not clear if the 
same findings hold true in vivo.  Furthermore, many studies have been done with VMAT over-
expression, which can result in false positives.  Although some look at direct interaction of 
proteins with VMAT2, some studies do not.  Thus, it is not always clear if observed effects on 
VMAT2 are direct or indirect.  In summary, relatively little has been investigated concerning 
VMAT2 regulation, leaving a major gap in our knowledge of this vital protein.  
1.3 DEGRADATION 
Degradation and synthesis processes work together to maintain proteostasis.  Once thought to be 
general and unmediated, we now understand that protein degradation is often a highly regulated 
process.  Protein degradation processes are in place to help regulate levels of proteins, remove 
damaged proteins, and act as a quality control mechanism.  The multitude of ways in which 
proteins can be degraded range from the simple to the very complex.  Ultimately, the 
mechanisms essential for managing degradation in the mammalian neuron can be boiled down to 
two—the 26S proteasome and the lysosome. 
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1.3.1 The ubiquitin-proteasome system 
The eukaryotic 26S proteasome is a protein complex consisting of an assembly of subunits.  
Shaped like a hollow cylinder, proteins destined for degradation are fed through and cleaved into 
small peptides.  The core of the proteasome, the 20S particle, contains proteolytic sites necessary 
for this function.  A regulatory 19S particle consists of a base and lid, capping one of the ends of 
the 20S particle.  The 19S particle regulates entry into the 20S particle, as well as the proteolytic 
activity of the core (Besche et al., 2009, Kim et al., 2011).  The 20S core has three main 
proteolytic sites with trypsin-like, chymotrpypsin-like, or caspase-like proteolyic activity.  
Theses sites are the main targets for the majority of proteasome inhibitors that have been 
developed, with most inhibiting one or more of these sites.  In addition to being used as research 
tools, proteasome inhibitors have also been developed for therapeutics, notably cancer treatment 
(Goldberg, 2007, Kisselev et al., 2012). 
 The delivery of substrates to the proteasome involves a complicated and highly 
choreographed series of events.  The primary way in which proteins are targeted to the 
proteasome is via the ubiquitin-proteasome system (UPS)—an all-encompassing term that 
describes these events, outlined in Figure 4.  The most common way proteins are targeted for 
proteasomal degradation is by ubiquitination (sometimes referred to as ubiquitylation).  This 
post-translational modification involves the formation of an isopeptide bond between the C-
terminus of ubiquitin, a small, cytoplasmic protein, and a residue of the substrate protein (Tai 
and Schuman, 2008, Komander, 2009). 
 24 
Ub E1 E2 E3
Ub
Ub Activation Ub Conjugation Ub Ligation
Ub Ub
Substrate
E3
Ub
Substrate
Polyubiquitination
Ub
Ub
Ub
Chaperoning 
and/or Diffusion
26S Proteasome
Ub
Substrate
Ub
Ub
Ub
DUB
Deubiquitination 
and Unfolding
Degradation
Ub
Ub Ub
Ub
 
Figure 4.  Overview of the UPS.  Following ubiquitin activation and conjugation by E1 and E2 enzymes, ubiquitin 
is then transferred to a substrate by an E3 ubiquitin protein ligase.  Further ubiquitin molecules are often added, 
forming a polyubiquitin chain.  The ubiquitinated substrate then diffuses or is chaperoned to the 26S proteasome.  At 
that point, the substrate is then deubiquitinated by enzymes (DUBs) and unfolded prior to degradation by the 26S 
proteasome. 
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What sounds like a simple modification in fact requires a series of reactions mediated by 
several enzymes.  Prior to being bound to a substrate, ubiquitin is first ‘activated’ by being 
conjugated to an enzyme, E1, in an ATP-dependent reaction.  Traditionally, ubiquitin is then 
transferred to the E2—the ubiquitin conjugating enzyme.  Finally, ubiquitin is transferred from 
the E2 to a substrate by the E3, an ubiquitin protein ligase.  While ubiquitin is typically attached 
to a lysine residue of the substrate protein, there are examples of other residues being 
ubiquitinated, including the N-terminus, cysteine, serine, or threonine residues (Ben-Saadon et 
al., 2004, Cadwell and Coscoy, 2005, Wang et al., 2007).  There are only a few activating and 
conjugating enzymes (under 100) identified in the mammalian system, but there exist over 500 
E3 ligases (Tai and Schuman, 2008).  The cellular localization of the E3 ligase and its ability to 
interact with substrates is one of the main factors conferring specificity in regulated degradation.   
 There is an even further degree of regulation built into this system.  The modification of a 
single ubiquitin molecule onto a substrate (monoubiquitination) is just one possible condition.  
There also exists muli-monoubiquitination, when multiple residues on a substrate are 
monoubiquitinated (Haglund et al., 2003).  Furthermore, polyubiquitination is common, when 
multiple ubiquitins form a chain off the original ubiquitin bound to the substrate.  Adding a layer 
of even more complexity, ubiquitin itself has multiple residues capable of being ubiquitinated; 
there are 8 potential polyubiquitin chain types identified.  The most common polyubiquitination 
chain associated with the UPS is K48; the ubiquitin chain is on the lysine 48 residue of the 
ubiquitin initially bonded to the substrate (Thrower et al., 2000).  K11 polyubiquitin chains are 
also associated with proteasomal degradation, but are less common (Baboshina and Haas, 1996, 
Xu et al., 2009).  Another more common polyubiquitin chain is K63, less often associated with 
proteasomal degradation.  Instead, K63 chains facilitate several other actions, including the 
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internalization of membrane proteins or lysosomal-mediated degradation, as well as playing a 
role in DNA repair (Hofmann and Pickart, 1999, Geetha et al., 2005, Duncan et al., 2006, 
Lauwers et al., 2009, Huang et al., 2013b).  Other chains include K6, K27, K29, K33 and Met1 
(also called linear, where the chain forms from the N-terminus of ubiquitin). These chains have a 
variety of other functions (targeting for lysosomal degradation, trafficking, mitophagy, etc.), but 
have not been as well characterized (Swatek and Komander, 2016).  Interestingly, K48 and K63 
chains form vastly different structures, with K63 chains having a more open conformation.  It is 
thought that these structural differences are what confer specificity, leading to the specific chains 
being ‘targeted’ for different pathways (Jacobson et al., 2009, Komander, 2009).  What 
determines linkage specificity, however, seems to be a combination of which E2 and/or E3 
participates in the process (Komander and Rape, 2012, Mattiroli and Sixma, 2014).  While the 
K48 and K63-linked polyubiquitin chains are traditionally segregated in terms of function, there 
are exceptions.  For example, there’s evidence that K63-linked polyubiquitin chains are capable 
of binding with the 26S proteasome, but are subject to deubiquitination more rapidly than K48-
linked chains, perhaps limiting proteasomal degradation of K63-linked polyubiquitinated 
proteins (Jacobson et al., 2009).  It has been suggested that there is redundancy within the 
degradation pathways; that is, degradation machinery accept multiple forms of ubiquitin chains 
(Xu et al., 2009). 
 Once the substrate is ‘tagged’ with ubiquitin, it is either chaperoned or diffuses to 
proteasomes.  As nicely reviewed by Grice and Nathan, once there, accessory proteins work with 
the 19s regulatory unit of the proteasome to recognize the ubiquitin molecule and aid in 
deubiquitination (Grice and Nathan, 2016).  Prior to entering the 20S core of the proteasome, 
deubiquitinating enzymes (DUBs) remove the ubiquitin molecule(s).  Proteins are then unfolded 
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before being degraded by the proteolytic sites in the 20S core particle.  These steps require a 
multitude of accessory proteins and enzymes, supplying an additional layer of variability and 
opportunity for regulation.  Many of the involved chaperones and accessory proteins have 
ubiquitin-interacting motifs, where they bind ubiquitin and in this way, ubiquitin serves as the 
main cellular signal for proteasome-mediated degradation (Winget and Mayor, 2010, Grice and 
Nathan, 2016). 
 The number of accessory proteins involved in the UPS has the ability to confer a great 
degree of specificity.  Because of this, proteasomal-mediated degradation is frequently thought 
of as being a more targeted approach to degradation, occurring under specific conditions.  There 
are instances in which the proteasome doesn’t have a regulatory role, per se, but rather a role in 
quality control.  One of the most studied of these processes is ERAD—endoplasmic reticulum-
associated degradation.  A brief overview of ERAD is presented in Figure 5.  In the ER, proteins 
are folded and processed prior to being exported to the Golgi.  During this, misfolded or 
damaged proteins are degraded by the process of ERAD, in which they are removed and 
degraded by cytosolic proteasomes.  Misfolded proteins are recognized and then chaperoned to 
the retrotranslocation machinery by chaperones within the ER—a number of which have been 
identified (Vembar and Brodsky, 2008, Stolz and Wolf, 2010).  The exact mechanisms of 
retrotranslocation—the movement of substrates across the ER lipid bilayer into the cytoplasm—
are not entirely known, although several plausible theories have been proposed (Brodsky, 2012, 
Christianson and Ye, 2014).  It is, however, generally agreed upon that ubiquitination plays a 
role.  E1, E2 and E3 ligases facilitate the ubiquitination of substrates, which again serves as a 
signal for proteasome-mediated degradation.  It is not entirely clear if ubiquitination also serves 
as a signal for the initiation of retrotranslocation.  Retrotranslocation is thought to occur through 
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a channel, although this has yet to be conclusively identified.  Several proteins/complexes have 
been suggested—the Sec61 complex, members of the Derlin family of proteins, and Hrd1, an E3 
ubiquitin ligase (Wiertz et al., 1996, Vashist and Ng, 2004, Carvalho et al., 2006, Scott and 
Schekman, 2008, Greenblatt et al., 2011, Huang et al., 2013a).  Regardless of which of these are 
mainly involved, it is clear that the ATPase p97/VCP complex is required for the process (Ye et 
al., 2001, Rabinovich et al., 2002, Richly et al., 2005).  This complex not only provides the 
energy required for retrotranslocation, but also associates with DUBs, ubiquitin ligases, and 
cofactors with ubiquitin recognition sites.  It is thought that retrotranslocation and subsequent 
degradation by the cytoplasmic proteasome are tightly coupled, although it is unclear if 
proteasomes are located near the p97/VCP complex or if substrates are shuttled to the 
proteasome (Christianson and Ye, 2014). 
An ongoing field of research, our knowledge of the UPS is constantly changing.  One 
such area of research is the contribution of UPS dysfunction to various diseases and disorders 
(Chaugule and Walden, 2016).  Perhaps some of the most striking examples are the 
‘proteopathies’—degenerative disorders characterized by protein misfolding and aggregate 
formation. Included in this group of disorders are devastating neurodegenerative diseases, such 
as Huntington’s, Alzheimer’s, and Parkinson’s disease.  While causal links haven’t been 
definitively determined, the pathologies of proteopathies have been partially attributed to UPS 
dysfunction. Focusing on PD, there’s considerable evidence indicating that the UPS and/or 
autophagy (discussed in the following section) dysfunction plays a role in the etiology of the 
disease, including the formation of Lewy bodies—aggregates primarily composed of α-synuclein 
and ubiquitinated proteins (Rubinsztein, 2006).  Patients with sporadic PD have reduced 
proteasomal activity  in  the substantia nigra compared to age-matched controls,  indicating  there  
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Figure 5.  Overview of ERAD.  Misfolded or damaged proteins are first recognized by a number of ER and 
cytosolic chaperones and accessory proteins (a partial list of examples are given).  The substrate is then chaperoned 
to the translocon (Declin, Hrd1, and/or Sec61) where it undergoes retrotranslocation with the aid of the p97/VCP 
complex.  The substrate is then ubiquitinated and targeted to the 26S proteasome for degradation.  Note that here, 
retrotranslocation is presented as an event that occurs prior to ubiquitination.  While this may be, it is also possible 
that the substrate may be ubiquitinated prior to retrotranslocation.   
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may be a fundamental deficit in the UPS (McNaught et al., 2003).  Various rare mutations that 
cause familial Parkinsonism encode proteins involved in the degradation machinery, such as 
parkin (an E3 ubiquitin ligase, also involved in mitophagy), UCHL1 (a de-ubiquitinating 
enzyme), and PINK1 (involved in mitochondrial dynamics, including mitophagy).  Additionally, 
disruptions in ERAD can result in aggregate formation and severe global dysfunction.  Just one 
example of many, mutations in p97/VCP cause inclusion-body myopathy with Paget’s disease of 
bone and frontotemporal dementia (Watts et al., 2004, Weihl et al., 2006). 
It should be noted that provided here are brief overviews of the UPS and ERAD.  The 
entire processes and components involved are complex.  It is becoming increasingly clear that 
while the UPS plays a significant role in protein degradation, ubiquitination has roles 
independent of degradation.  There are examples of ubiquitin-independent proteasomal 
degradation of substrates, further indicating there are aspects of the system we do not yet fully 
understand (Kravtsova-Ivantsiv and Ciechanover, 2012). 
1.3.2 Degradation by the lysosome 
The other primary method of protein degradation in eukaryotic cells is by the lysosome.  
Membrane-bound structures, lysosomes contain specific hydrolases that digest proteins.  The pH 
of lysosomes is acidic, maintained by vacuolar H+-ATPase pumps (Mindell, 2012).  While 
lysosomes contain over 50 known hydroylases, the most well researched are the cathepsins—a 
group of proteases that function optimally under the acidic lysosomal conditions (Appelqvist et 
al., 2013).  The lysosome has roles in multiple cellular processes, although here I will focus on 
its role in degradation (Settembre et al., 2013).  Unlike the UPS, lysosomes typically degrade 
membrane proteins, extracellular material, and macromolecules.  Once thought to be associated 
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with unregulated, bulk degradation, it is now clear that targeting to the lysosome for degradation 
can be just as specific as in the UPS.   
A major group of proteins that are degraded by lysosomes are plasma membrane proteins 
through the endo-lysosomal pathway, represented in Figure 6.  Reviewed by Grant and others, 
essentially, these proteins are internalized through endocytosis and are retained on early 
endosomes—membrane bound structures that serve as a sorting area (Grant and Donaldson, 
2009, Saftig and Klumperman, 2009, Sorkin and von Zastrow, 2009).  Recycling endosomes 
traffic proteins back to the plasma membrane if that is their fate.  Early endosomes are then 
converted into multivesicular bodies (MVBs, also called late endosomes), where further sorting 
is done.  At this point, some proteins are transported back to the trans-Golgi network.  If not, 
these proteins will be degraded by the lysosome when the MVBs fuse with the lysosomal 
membrane (Grant and Donaldson, 2009, Saftig and Klumperman, 2009, Sorkin and von Zastrow, 
2009, Appelqvist et al., 2013). 
As with the UPS description, this is a rather simplified view.  A multitude of accessory 
proteins are involved with this process and the maturation of endosomes is complicated, 
involving pH changes, exchanges of membrane, trafficking of components, and fusion events 
(Luzio et al., 2007).  For example, ubiquitination is believed to play a role in the internalization 
and targeting of receptors, transporters, and channels to the lysosome for degradation.  Several of 
these rely on ubiquitination—although in some cases the modification seems sufficient, but not 
necessary for endocytosis, implying there are multiple mechanisms for endocytosis and perhaps, 
redundancy within the system (Sigismund et al., 2005, Goh et al., 2010, MacGurn et al., 2012).  
Monoubiquitination and K63-linked polyubiquitin chains have been most associated with 
lysosomal degradation through this pathway (Haglund et al., 2003, Duncan et al., 2006, Lauwers 
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et al., 2009, Vina-Vilaseca and Sorkin, 2010, Stringer and Piper, 2011).  Accessory proteins, 
likely members of the epsin family, at the plasma membrane have ubiquitin interacting motifs, 
which allow them to recognize and sort the ubiquitinated plasma membrane proteins (Polo et al., 
2002, Sigismund et al., 2005).  A group of proteins called ESCRTs (endosomal sorting 
complexes required for transport) are thought to play a role in the sorting of these ubiquitinated 
proteins once they are in endosomes (MacGurn et al., 2012, Hurley, 2015).  These ESCRTs also 
aid in the formation of intraluminal vesicles, vesicles within MVBs containing transmembrane 
proteins to be degraded.  ESCRTs interact with a variety of E3 ligases and DUBs, indicating that 
degradation signals can be added or removed even at this stage. 
Lysosomes are also capable of degrading cytosolic proteins and intracellular components.  
Many of these substrates come to the lysosome through autophagy, a term that encompasses 
several different processes.  Microautophagy refers to when cytosolic material is engulfed 
directly at the lysosomal membrane.  Chaperone-mediated autophagy is the process by which 
cytosolic proteins are shuttled to the lysosome for degradation.  Finally, macroautophagy, the 
main autophagy pathway, involves the formation of autophagosomes—membrane-bound 
structures that form around cytoplasm and/or organelles, engulf them, and then fuse with the 
lysosome for degradation of the contents. 
In chaperone-mediated autophagy, cytosolic proteins are more specifically targeted for 
degradation by the lysosome.  These substrates typically contain a motif (KFERQ, or similar to) 
that’s recognized by chaperones (Dice, 1990).   The main chaperone involved in this process is 
Hsc70, although other accessory chaperones, like Hsp40 and Hsp90, may also be involved 
(Chiang et al., 1989, Agarraberes and Dice, 2001).  Interestingly, Hsc70 has been shown to 
interact directly with VMAT2 and reduce uptake activity,  although the mechanism of this action  
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Figure 6.  Overview of the endo-lysosomal pathway.  Plasma membrane proteins are endocytosed, sometimes (but 
not always) with ubiquitin acting as an internalization sequence.  In early endosomes, proteins are either trafficked 
to recycling endosomes for transport back to the plasma membrane or trafficked to MVBs, if targeted for 
degradation.  Ultimately, MVBs will fuse with lysosomes, which will degrade the substrate. 
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is unknown (Requena et al., 2009).  Lamp2a, a lysosomal membrane protein, is believed to be 
the primary receptor for these chaperones/substrates, although there’s indication that other 
receptors undertake this function in the absence of Lamp2a (Cuervo and Dice, 1996, Eskelinen et 
al., 2004).  The process of chaperone-mediated autophagy is important for quality control, but 
along with macroautophagy, also seems to be an induced pathway in response to stress, including 
starvation and oxidative stress (Wing et al., 1991, Kiffin et al., 2004). 
Unlike chaperone-mediated autophagy, macroautophagy involves an impressive array of 
signaling pathways and proteins—not only for induction and substrate recognition, but also for 
autophagosome formation and subsequent fusion with lysosomes.  Of note, selective autophagy 
utilizes the modification of substrates with ubiquitin-like proteins, much as in the UPS system 
(Mizushima et al., 1998, Welchman et al., 2005, Bento et al., 2016).  In fact, there’s evidence 
that ubiquitinated proteins (notably, ubiquitinated, aggregated proteins) can be recognized by 
autophagosome receptors and degraded through the process of autophagy, highlighting the 
importance of ubiquitination across all degradation pathways (Komatsu et al., 2007, Kim et al., 
2008, Kirkin et al., 2009a, Kirkin et al., 2009b).  Macroautophagy is essential as a mechanism of 
quality control within the cell, acting as a means of degradation for aggregated proteins and 
damaged organelles.  While autophagy is relatively unspecific under certain circumstances 
(stress, or starvation, for example), it can also be extremely selective.  For example, the 
degradation of damaged organelles is a very selective process.  The best characterized is 
mitophagy, in which damaged mitochondria are identified and selectively targeted for 
autophagy.  Originally believed to play a role in programmed cell death, it’s now under debate as 
to whether autophagy induction causes cell death or is induced as a means to cope with cellular 
stress.  Paradoxically, linked to both cell death and cell survival, the exact role of autophagy 
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seems to depend on the context and circumstances under which autophagy is induced (Feng et 
al., 2014, Mrschtik and Ryan, 2015). 
As with the UPS, lysosomal dysfunction can cause a number of diseases.  There’s a large 
class (over 50) of metabolic disorders categorized as ‘lysosomal storage disorders’ that are 
caused by mutations of varying lysosomal proteins (Platt et al., 2012).  Depending on the 
disorder, symptoms vary, but can result in developmental delay or early death.  Experimentally, 
disturbances in autophagy result in severe deficits; neuronal Atg5 and Atg7 (essential 
components of autophagosome formation) knockout mice develop inclusions, age-related motor-
deficits, and reduced vitality (Hara et al., 2006, Komatsu et al., 2006).  As with the UPS, deficits 
in autophagy are thought to play a role in proteopathies.  Mutated forms of α-synuclein that 
cause PD, A30P and A53T, block Lamp2a, which has a role in chaperone mediated autophagy 
(Cuervo et al., 2004).  Under these circumstances, mutant α-synuclein and other substrates are no 
longer degraded, perhaps contributing to the formation of toxic α-synuclein protofibrils.  
Notably, patients with Gaucher’s disease, a lysosomal storage disorder resulting from 
glucocerebrosidase mutations, are five times more likely to develop Parkinsonism (Sidransky et 
al., 2009).  Although it is unclear how exactly the two disorders are related, it suggests a link 
between lysosomal dysfunction and Parkinsonism. 
1.3.3 Degradation of synaptic vesicle proteins 
There is substantial evidence for the degradation of plasma membrane transmembrane proteins 
through the endo-lysosomal pathway.  It is less clear how synaptic vesicular proteins are 
degraded; aspects of synaptic vesicle biogenesis and recycling are also less understood.  
Reviewed extensively by Rizzoli, the classic view of neuronal synaptic vesicle biogenesis is 
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simplified here.  Following synthesis and ER/Golgi processing, synaptic vesicular proteins seem 
to group in patches within the Golgi (Rizzoli, 2014).  “Precursor vesicles” bud from the Golgi 
and undergo anterograde transport to the presynaptic terminal.  These vesicles fuse with the 
plasma membrane, where synaptic vesicular proteins will diffuse and again sort into distinct 
patches.  Synaptic vesicles form when endocytosis is triggered and at this point, they may fuse to 
endosomes for further sorting, although this process is poorly understood (Hoopmann et al., 
2010).  The synaptic vesicles are then filled with neurotransmitter and dock at the active zone 
prior to exocytosis.  Following exocytosis, membrane and synaptic vesicular components are 
internalized and recycled locally to re-form vesicles through a clathrin-dependent mechanism 
(‘fast’ endocytosis) (Holtzman et al., 1971, Heuser and Reese, 1973, Koenig and Ikeda, 1996, de 
Lange et al., 2003, Saheki and De Camilli, 2012).  A second pathway has been proposed, where 
synaptic vesicles reform from an endosomal intermediate in what has been termed ‘bulk’ or 
‘slow’ endocytosis (Faundez et al., 1998, Rizzoli et al., 2006, Rizzoli, 2014, Kokotos and 
Cousin, 2015). For VMAT2, endocytosis depends on the C-terminal motif KEEKMAIL, 
specifically the isoleucine-leucine pair that may be a recognition site for AP-2, a protein 
involved in clathrin-mediated endocytosis (Tan et al., 1998).  For reference, the KEEKMAIL 
motif is indicated in Figure 1.  Interestingly, there is some evidence indicating that VMAT2 and 
VGLUT1, the glutamatergic vesicular transporter, have different recycling pathways (Croft et 
al., 2005, Onoa et al., 2010, Grygoruk et al., 2014).  For example, when expressed in primary 
hippocampal or dopaminergic ventral midbrain neurons, VMAT2 had a slower endocytosis rate 
than VGLUT1 following stimulation, suggesting the rate differences are the result of the 
property of the protein and not cell type.  The authors suggest VMAT2 may diffuse more within 
the plasma membrane, but were not able to directly assess this (Onoa et al., 2010).  
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 The existence of proteasomes, but not lysosomes, in the presynaptic terminal has been 
well established.  Because of this, there exist two predominant possibilities for the degradation of 
synaptic vesicular proteins: (1) individual proteins are degraded at the synapse by the UPS or (2) 
vesicles or vesicular components are sorted at an endosome intermediate following endocytosis 
and shuttled via retrograde transport back to the cell body for lysosomal degradation.  The 
importance of UPS function has been implicated in a number of processes at the presynaptic 
terminal, influencing vesicle dynamics and neurotransmitter release (Speese et al., 2003, 
Willeumier et al., 2006, Yao et al., 2007, Rinetti and Schweizer, 2010).  The potential for its 
mediation of synaptic vesicular protein degradation, however, has not been fully explored.  Both 
syntaxin and synaptophysin have been proposed to be degraded in a proteasome and ubiquitin-
dependent manner (Chin et al., 2002, Wheeler et al., 2002).  However, these studies were 
performed in heterologous expression systems and results have not been confirmed with 
endogenous protein. 
The dislocation of transmembrane, glycosylated proteins necessitates a large energy 
requirement.  Because of this, it seems unlikely that transmembrane vesicular proteins could be 
degraded by the UPS.  There are very few instances of observed post-ER retrotranslocation of 
proteins.  One example is the p97-mediated retrotranslocation of Mfn1 and Mcl1, two outer 
mitochondrial transmembrane proteins (Xu et al., 2011).  Another example comes from work by 
Peter Espenshade.  He and his group have worked to establish the role of a Golgi quality control 
mechanism for proteins, similar to ERAD.  They have established, in yeast, Golgi E3 ligase 
complexes that participate with Cdc48 (p97 in mammals) in the retrotranslocation of 
transmembrane substrates (Stewart et al., 2011, Tong et al., 2014, Hwang et al., 2016).  
However, retrotranslocation of these proteins is not from the plasma membrane or synaptic 
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vesicular membrane.  To this author’s knowledge, retrotranslocation of glycosylated, 
transmembrane proteins from plasma or synaptic vesicular membranes has not been directly 
demonstrated.  Support for lysosome-mediated vesicular protein degradation comes from 
evidence of retrograde transport back to the cell body.  Several researchers have found evidence 
indicating synaptic vesicles and their components undergo retrograde transport back to the cell 
body (Tsukita and Ishikawa, 1980, Li et al., 1996, Li and Dahlstrom, 1997).  However, none 
observed lysosomal-dependent degradation directly, rather an assumption was made that the 
transport back to the cell body was for degradation.  The lack of research in the area of synaptic 
vesicular degradation underlies how difficult this topic is to study.  More recently, Patrik 
Verstreken’s group has undertaken this difficult task.  Using Drosophila as a model system, they 
have demonstrated that loss of a GTPase activator increases synaptic recycling to endosomes 
(Uytterhoeven et al., 2011).  Loss of dor, an orthologue of the human Vps18 (a member of the 
HOPS complex that promotes trafficking of vesicles to lysosomes) also results in defective 
trafficking to lysosomes, providing the identity of potential molecular components involved in 
vesicular protein degradation (Fernandes et al., 2014).  Lysosomal-mediated degradation of 
VMAT2 has been proposed by researchers, including Annette Fleckenstein’s group (German et 
al., 2015, Sulzer et al., 2016).  However, there is no data that directly supports this model of 
lysosome-mediated VMAT2 degradation. 
There is a dearth of information regarding the degradation mechanisms of vesicular 
proteins, including transporters.  Because of this, we sought to identify the mechanisms involved 
in VMAT2 degradation.  To accomplish this, we used pharmacological tools to inhibit 
degradation processes and then examined VMAT2 levels, cellular localization and 
ubiquitination.  We believe that the regulation of VMAT2 is important to study, as VMAT2 
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plays an essential role in monoaminergic signaling.  The goal of this thesis work was to identify 
the primary machinery by which VMAT2 is degraded in order to begin to understand the 
processes involved and contribute knowledge to the field of synaptic vesicular protein 
degradation. 
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2.0  MATERIALS AND METHODS 
2.1 MODEL SYSTEM 
As a model system, I utilized PC12 cells, a rat pheochromocytoma cell line.  PC12 cells are used 
as a model for exocytosis, as they contain vesicles and synthesize dopamine (and sometimes 
norepinephrine) (Greene and Tischler, 1976, Schweitzer et al., 1995, Kozminski et al., 1998, 
Pothos et al., 2000).  PC12 cells contain small, clear vesicles and large dense core vesicles (or 
granules) that are comparable to neuronal synaptic vesicles and dense core vesicles, respectively.  
PC12 cells have endogenous VMAT1 that preferentially localizes to large dense core vesicles 
(Liu et al., 1994, Weihe et al., 1996).  When differentiated with nerve growth factor (NGF), 
PC12 cells extend neurite-like projections, develop vesicle-rich varicosities along some of these 
processes, and more closely resemble the phenotype of sympathetic ganglion neurons than when 
undifferentiated (Westerink and Ewing, 2008). 
PC12 cells were obtained from the American Type Culture Collection (Manassas, VA).  
Cells were cultured in DMEM (Dulbecco’s modified Eagle’s medium) with 5% fetal bovine 
serum, 10% horse serum, and 1% penicillin/streptomycin at 37°C and 10% carbon dioxide.   
Where noted, cells were transiently transfected with rat VMAT2 subcloned into the peGFP-N2 
vector (VMAT2-GFP, so there’s a GFP tag on the C terminus of VMAT2).  Transient expression 
of 10 μg VMAT2-GFP cDNA with Lipofectamine 2000 (Invitrogen) was performed according to 
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manufacturer’s instructions (2.5 μL Lipofectamine per μg of cDNA) and cells were transfected 
48 hours prior to use.  The majority of experiments were done with PC12 cells stably expressing 
VMAT2-GFP.  Cells were transfected with VMAT2-GFP cDNA, then sorted twice via flow 
cytometry for GFP.  The cell line was then maintained in 50 μg/mL G418 sulfate.   
Using crude vesicular preparations, I demonstrated that this VMAT2-GFP construct is 
capable of serotonin uptake (shown in Appendix A).  Even though PC12 cells have endogenous 
VMAT1, an over-expression system of GFP-tagged VMAT2 was used for a number of reasons.  
For one, the goal of the project was to investigate the mechanisms of neuronal VMAT 
degradation.  While VMAT1 and VMAT2 sequences are somewhat similar, there are major 
differences, especially in the cytoplasmic and large intravesicular domains.  The GFP tag was 
used, in part, because it aided in sorting for development of a stable cell line via flow cytometry.  
Additionally, VMAT2 antibodies can be unreliable, especially for microscopy.  While not 
impossible to perform experiments with untagged VMAT2, the GFP tag provided a means for 
reliable detection of VMAT2.  As demonstrated in Figure 7, a GFP antibody used frequently in 
these studies detects two main VMAT2 bands—a ‘smear’ around 120 kDa and a more compact 
band around 75 kDa.  Others have described three un-tagged VMAT2 bands:  a mature, 
glycosylated form at around 75 kDa, a partially glycosylated form at approximately 55 kDa, and 
a native form at the lowest molecular weight, 45 kDa (Cruz-Muros et al., 2008).  I was unable to 
detect the lowest molecular weight form with the GFP antibody. 
EndoH (Endoglycosidase H) digestion was used to confirm the cellular localization of the 
two bands detected.  EndoH is an enzyme that cleaves high-mannose and hybrid 
oligosaccharides in the core region.  EndoH does not cleave complex glycans and therefore does 
not cleave proteins that have already undergone further processing in the Golgi body.  This 
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enzyme can therefore be used as a way of determining the processing stage of proteins—EndoH 
digestion will result in a molecular weight shift of N-glycosylated proteins in the endoplasmic 
reticulum (ER), but not proteins that have exited the ER (Freeze and Kranz, 2010).  PC12 cells 
stably expressing VMAT2-GFP were lysed, equal protein amounts incubated with EndoH and 
reaction buffer (Promega, catalog #V487A, #V487B) for 4 hours at 37°, and subjected to SDS-
PAGE.  Membranes were probed with anti-GFP or anti-tubulin and compared to samples not 
treated with EndoH.  As shown in Figure 8, the molecular weight of the VMAT2 smear at 120 
kDa remained unchanged following EndoH digestion.  The lower, 75 kDa band shifted following 
EndoH digestion, indicating that it is an immature form of VMAT2 that was still undergoing 
processing in the ER at the time of lysis.  These results confirm what others have demonstrated 
and concluded about VMAT2 forms and glycosylation states (Yelin et al., 1998, Jassen et al., 
2005, Cruz-Muros et al., 2008).  For the remainder of this document, the 120 kDa band will be 
referred to as the ‘mature’ form of VMAT2 and the 75kDa band as the ‘immature’ form. 
 
Figure 7.  Specificity of GFP antibody.  PC12 cells were transfected with 10 μg peGFP-N2 empty 
vector or 10 μg VMAT2-GFP cloned into peGFP-N2.  These cells and untransfected PC12 cells 
were lysed and subjected to immunoblotting.  The membrane was probed with anti-GFP, an 
antibody frequently used in this project, to detect VMAT2-GFP. 
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Figure 8.  Endo H Digestions.  PC12 cells stably expressing VMAT2-GFP were treated with 
DMSO vehicle, MG132, or E64/AEBSF for 6 hours.  Cells were lysed and then digested with 
Endo H for 4 hours.  Note how the molecular weight of the mature form around 120 kD remains 
the same.  The molecular weight of the immature band around 75 kD decreases following Endo H 
treatment, confirming location in the endoplasmic reticulum and status as the immature VMAT2 
band. 
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2.2 METHODS 
2.2.1 Antibodies 
For VMAT2 detection, anti-GFP was used at a 1:1000 dilution (Sigma-Aldrich, clone GFP-20, 
catalog #G6539).  Anti-tubulin was used at 1:2000 (Sigma-Aldrich, clone B-5-1-2, catalog 
#T6074).  For ubiquitin detection, anti-ubiquitin was used at 1:500 (Santa Cruz, clone PD41, 
catalog #sc-8017).  Lysine 48-specific ubiquitin antibody (Millipore, clone Apu2, catalog # 05-
1307) and lysine 63-specific ubiquitin antibody (Millipore, clone Apu3, catalog #05-1308) were 
also used at a 1:500 dilution.  Anti-parkin was used at a 1:1000 dilution (Santa Cruz, clone 
PRK8, catalog # sc-32282).  For rabbit antibodies, horseradish peroxidase-linked protein A (GE 
Healthcare, catalog #NA9120V) was used at a 1:4000 dilution as secondary.  For mouse 
antibodies, goat anti-Mouse IgG (H+L)-horseradish peroxidase conjugate (BioRad catalog # 
170-6516) was used at 1:5000 as secondary. 
In immunocytochemistry experiments, two antibodies for GFP were used:  monoclonal 
anti-GFP from Sigma-Aldrich (used at a 1:1000 dilution, clone GFP-20, catalog #G6539) or 
rabbit polyclonal anti-GFP from Abcam (used at a 1:2000 dilution, catalog #ab290).  Alexa 
Fluor® 488-conjugated goat anti-rabbit IgG (H&L) (Jackson ImmunoReseach, catalog #111-
545-003) and Alexa Fluor® 488-conjugated goat anti-mouse IgG (H&L) (Jackson 
ImmunoReseach, catalog #115-545-003) were both used as secondary antibodies at a 1:500 
dilution for the GFP antibodies.  As a marker for the endoplasmic reticulum, I used anti-PDI 
from Abcam (clone RL90, catalog #ab2792) at a 1:1000 dilution and goat anti-mouse IgG H&L 
Alexa Fluor® 647 (Abcam, ab150115) at a 1:500 dilution.  Two different LAMP1 antibodies 
were utilized as markers of lysosomes/endosomes:  rabbit polyclonal anti-LAMP1 (1:100, 
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Abcam, catalog #ab24170) or monoclonal anti-LAMP1 (1:50, H4A3, obtained from the 
Developmental Studies Hybridoma Bank (DSHB), originally deposited by JT August and JEK 
Hildreth (citation).  The secondary antibody utilized for polyclonal anti-LAMP1 was Cy™3-
conjugated goat anti-rabbit IgG (H&L) (1:1000, Jackson ImmunoResearch, catalog #111-165-
003) and for monoclonal LAMP1, Alexa Fluor® 647 at a 1:1000 dilution.  
2.2.2 Drug treatments 
Cycloheximide (Sigma-Aldrich), E64 (MP Biochemicals), MG132 (Cayman Chemical), 
Epoxomicin (Abcam), and Eeyarestatin I (Tocris Bioscience) were dissolved in DMSO while 
AEBSF (MP Biochemicals) was dissolved in water.  Cells were plated in poly-D-lysine-coated 
plates 24 hours prior to drug addition and then were treated with drugs for up to 18 hours at the 
following concentrations:  50 μg/mL cycloheximide, 25 μM E64, 200 μM AEBSF, 10 μM 
MG132, 250 nM Epoxomicin, 10 μM Eeyarestatin I.  Following treatments, cells were washed 2 
times with ice-cold PBS and lysed for 1 hour at 4°C with rotation in 20 mM HEPES, 125 mM 
sodium chloride, 1 mM EDTA, 1 mM EGTA, 10% glycerol, pH 7.4 in addition to 1% Triton x-
100, protease inhibitor cocktail (Millipore, contains AEBSF, aprotinin, E64, EDTA, and 
leupeptin) and 10 mM N-ethylmaleimide (NEM) (to inhibit de-ubiquitination). Lysates were 
centrifuged at 10,000 x g for 10 minutes at 4°C and the supernatant was used for subsequent 
analysis. Protein levels were determined using the BioRad DC protein assay (a colorimetric 
assay similar to a Lowry assay) and values read on a spectrophotometer at 750 nm.    
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2.2.3 Immunoblotting 
Cell lysates were denatured in western blot sample buffer (60 mM Tris-HCl (pH 6.8), 25% 
glycerol, 2% SDS, 14.4 mM β-mercaptoethanol, 0.1% bromophenol blue) for 30 minutes at 
37°C.  Equal amounts of protein were loaded onto 8 or 10% Tris SDS-polyacrylamide gels.  Gels 
were ran in 25 mM Tris, 250 mM glycine, 0.1% SDS running buffer.  Transfer onto 
nitrocellulose membranes were performed at 4°C in 25 mM Tris, 192 mM glycine, 20% 
methanol transfer buffer.  Membranes were then blocked in 5% milk for 1 hour at room 
temperature with rocking and then incubated overnight in primary antibody (in 2.5% milk) at 
4°C with rocking.  Membranes were washed 3 times (10 minutes each) with oscillation in TBST 
(50 mM Tris, 150 mM sodium chloride, 0.2% Tween-20, pH 7.5), incubated in secondary 
antibody for 1 hour at room temperature with rocking, and then washed another 3 times (10 
minutes each) in TBST at room temperature.  Chemiluminescent signal was detected using 
SuperSignal® West Pico kit (Thermo Fisher Scientific). 
2.2.4 Immunoprecipitations 
PC12 cells stably expressing VMAT2-GFP were plated onto poly-D-lysine-coated coverslips and 
treated with DMSO vehicle, 10 μM MG132, or 25 μM E64 and 200 μM AEBSF for 6 or 12 
hours.  Cells were washed twice with ice-cold PBS and lysed for 1 hour at 4°C with rotation in 
RIPA buffer (50 mM Tris, 150 mM sodium chloride, 0.1% SDS, 0.5% sodium deoxycholate, pH 
8.0 with 1% Triton x-100, protease inhibitor cocktail and 10 mM NEM.  Lysates were 
centrifuged at 10,000 rpm for 10 minutes and the supernatant was used for subsequent analysis.  
Protein levels were determined as described above.  1 mg/mL lysate was incubated with protease 
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inhibitor cocktail, NEM, and 10 μL anti-VMAT2 (Santa Cruz, C20 clone, catalog #sc-7721) 
overnight at 4°C with rotation.  As an ‘IgG’ control, goat IgG (Millipore, catalog #PP40) was 
substituted for VMAT2 antibody.  As a ‘buffer’ control, RIPA buffer was substituted for cell 
lysate.  Following overnight incubation, 80 μL protein G sepharose beads (washed in PBS, then 
reconstituted 1:1 in RIPA) was added and further incubated for 2 hours at 4°C with rotation.  
Beads were washed twice in RIPA for 5 minutes each, then one time in PBS for 5 minutes.  
Beads were then suspended in western blot sample buffer and subjected to immunoblotting as 
described above. 
VMAT2-parkin co-immunoprecipitations were performed largely as described above.  
PC12 cells were transfected with 10 μg VMAT2-GFP and 10 μg human parkin cloned into a 
pcDNA33.1 vector using Lipofectamine 2000.  48 hours post-transfection, cells were lysed in 20 
mM HEPES, 125 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 10% glycerol, pH 7.4 in 
addition to 1% Triton x-100 and protease inhibitor cocktail.  VMAT2 immunoprecipitation was 
performed as described in the above paragraph.  Following overnight incubation in VMAT2 
antibody and 2 hours incubation with 80 μL Protein G sepharose, beads were washed for 5 
minutes each in buffer (50 mM Tris, 150 mM sodium chloride, pH 8) plus 1% Triton x-100, 
buffer alone (just 50 mM Tris, 150 mM sodium chloride, pH 8), and PBS.  Immunoblotting was 
performed as described and membranes were probed with anti-GFP and anti-Parkin. 
2.2.5 GST pull downs 
VMAT2 cDNA fragments encoding residues 1-18 (the N-terminus), 268-292 (the third 
cytoplasmic loop), or 466-514 (the C-terminus) were subcloned into the pGEX4T-1 vector and 
were purified from E. Coli using gluthathione-sepharose 4 fast-flow (GE Healthcare).  
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Approximately equal amounts of GST-VMAT2 fusion proteins comprising either the VMAT2 
N-terminus (VMAT2-N), cytosolic loop (VMAT2-L), VMAT2 C-terminus (VMAT2-C), or GST 
alone, were incubated with 1 mg/mL whole rat brain homogenate overnight at 4°C with rotation.  
Beads were washed with 50 mM Tris, 150 mM sodium chloride, pH 8 first with, then without 
1% Triton tx-100.  Following a final wash with PBS, beads were then re-suspended in western 
blot sample buffer and subjected to immunoblotting as described above.  Prior to blocking, 
membranes were incubated with Ponceau red stain to visualize relative levels of VMAT2-GST 
fusion proteins.  Membranes were then probed with anti-parkin to detect the ability of the GST-
VMAT2 fusion proteins to ‘pull down’ parkin. 
2.2.6 Pulse-chase assay 
This pulse-chase protocol is modified from a number of other studies, most of which examine 
half-lives of transmembrane proteins (Zhang et al., 2000, Imai et al., 2001, Chin et al., 2002, 
Moriyoshi et al., 2004).  PC12 cells stably expressing VMAT2-GFP were plated onto poly-D-
lysine-coated 60 mm plates.  The following day, cells were washed twice with PBS and 
incubated in cysteine/methionine-free DMEM for 1 hour.  When experiments were performed to 
assess the impact of proteasomal inhibition on VMAT2 half-life, cells were pre-incubated with 
DMSO vehicle or 5 μM MG132 for two hours and then ‘pulsed’ with 100 μCi [35S] 
methionine/cysteine mix (EasyTag™ EXPRESS35S Protein Labeling Mix, Perkin Elmer, catalog 
#NEG7720) for 1 hour.  When experiments were performed to assess the impact of lysosomal 
inhibition on VMAT2 half-life, cells were ‘pulsed’ for 24 hours to maximize labeling of mature 
VMAT2.  Following incubation with 35S, plates were washed twice with media and ‘chased’ in 
DMEM containing an excess (5 mM) of methionine and cystine.  DMSO or 5 μM MG132 was 
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added to chase media and cells were lysed immediately or after 1, 2, 4, 6, or 8 hours incubation.  
Alternatively, following a 24 hour ‘pulse’, cells were washed, incubated in chase media 
containing DMSO or 25 μM E64 and 200 μM AEBSF, and lysed immediately or after 6, 12, 24, 
36, or 48 hours incubation.  Cells were lysed in RIPA buffer as described previously.  Protein 
content was determined and a portion of lysate was subjected to SDS-PAGE as described.  
Membranes were probed with anti-GFP and anti-tubulin to assess VMAT2-GFP levels. 
500 μg of the remaining cell lysate was subjected to immunoprecipitation.  Lysate was 
pre-cleared with 40 μL protein G beads (1:1 in RIPA), protein inhibitor cocktail, and 10 mM 
NEM for 2 hours at 4°C with rotation.  Samples were centrifuged and the supernatant was then 
incubated overnight with 5 μL anti-VMAT2 (Santa Cruz, C20 clone, catalog #sc-7721) at 4°C 
with rotation.  60 μL protein G beads (1:1 in RIPA) were then added for 1 hour incubation and 
beads were then washed for 5 minutes once with RIPA and then twice with PBS.  Beads were 
then re-suspended in sample buffer described previously and samples were subjected to SDS-
PAGE.  A portion of immunoprecipitation elute was used for autoradiography, while a smaller 
portion was then used for immunoblotting and probed for anti-GFP (to determine 
immunoprecipitation consistency). For autoradiography, gels were dried and exposed onto 
Carestream Kodak BioMax MS film (Sigma, catalog #2363022) at -80°C for 2-5 days until 
developed. 
2.2.7 Immunocytochemistry 
PC12 cells stably expressing VMAT2-GFP were plated onto poly-D-lysine-coated glass 
coverslips and maintained in DMEM containing 0.05% fetal bovine serum and 1% 
penicillin/streptomycin.  Cells were differentiated with 100 ng/mL nerve growth factor (NGF, 
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Promega, catalog #G5141) for 3 days, given every other day.  During this time, cells developed 
neurite-like extensions to other cells and a more neuronal-like morphology.  Following 
differentiation, cells were treated with DMSO vehicle for 6 or 24 hours, 5 μM MG132 for 6 
hours, or 25 μM E64/200 μM AEBSF for 24 hours.  Staining was performed at room temperature 
following a protocol established by the Center for Biologic Imaging at University of Pittsburgh.  
Coverslips were washed 3 times with PBS and fixed in 2% paraformaldehyde for 15 minutes.  
Cells were then washed another 2 times with PBS and permeabilized with 0.1% Triton x-100 for 
15 minutes.  Cells were washed 3 times with PBS, a further 5 times with 0.5% BSA in PBS 
(PBB) and blocked in 5% normal goal serum diluted in PBB for 45 minutes.  Samples were then 
washed 4 times with PBB and incubated in primary antibody diluted in PBB for 1 hour.  Non-
specific staining by secondary antibodies were assessed by incubating coverslips with PBB 
instead of primary antibody.  Coverslips were washed 4 times in PBB and incubated in 
secondary antibody diluted in PBB for 45 minutes.  Cells were washed with PBB 5 times and 
incubated in 1 mg/100 mL Hoeschst stain for approximately 30 seconds to stain nuclei.  
Coverslips were then washed 4 times with PBS and affixed to slides with fluoromount.  Slides 
were stored at 4°C until imaging.  1 micron thick Z stack images were obtained on a Nikon A1R 
confocal using a 60x oil objective and the NIS Elements Imaging software.  Co-localization 
analysis to determine Manders’ Coefficients was performed using ImageJ software (NIH, 
Bethesda, MD, JACoP plugin) following background subtraction. 
2.2.8 Live Cell Imaging 
These experiments were performed at the McKnight Brain Institute of the University of Florida 
(Gainesville, Florida) under the excellent guidance of Dr. Habibeh Khoshbouei and Danielle 
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Sambo.  PC12 cells stably expressing VMAT2-GFP were plated into poly-D-lysine-coated Mat-
Tek dishes (#P35G-1.5-14-C) and maintained in phenol-red-free DMEM containing 0.05% fetal 
bovine serum and 1% penicillin/streptomycin.  Cells were differentiated with 100 ng/mL nerve 
growth factor (NGF, Promega, catalog #G5141) for 3-5 days, given every other day, until cells 
displayed neuronal-like morphology.  Cells were imaged on a Nikon A1RMPsi-STORM4.0 
multiphoton/super resolution imaging system with CO2 and thermal regulation (kept at 5% and 
37°C, respectively).  Images were obtained using a 60x oil objective and the NIS Elements 
Imaging software.  Z stack sampling was performed every 30 minutes at multiple points in the 
dishes following the addition of DMSO vehicle, 5 µM MG132, or 25 µM E64/200 µM AEBSF.  
Whole cell fluorescence intensity analysis was performed using Nikon NIS Elements software 
after background subtraction.  Line analysis was performed using ImageJ, also following 
background subtraction. 
2.2.9 Vesicular Uptake 
Crude vesicular preparations were made as described in Parra et al. 2008 (Parra et al., 2008).  
PC12 cells stably expressing VMAT2-GFP were washed two times with PBS and re-suspended 
in 150 mM sodium chloride, 10 mM HEPES, 0.5 mM EGTA, 0.1 mM magnesium chloride, 320 
mM sucrose, pH 7.4 plus protease inhibitor cocktail.  Cells were homogenized by 10 strokes in a 
glass/teflon hand homogenizer and then passed through a 25 gauge needles 25 times.  
Homogenate was centrifuged at 4°C for 5 minutes at 1000 x g.  The supernatant (S1) was 
centrifuged at 4°C for 35 minutes at 27000 x g.  The resulting supernatant (S2) was further 
centrifuged at 4°C for 2 hours at 180,000 x g.  The subsequent pellet (P3, a crude vesicular-
enriched prep) was used in vesicular uptake assays. 
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Radioactive vesicular uptake assays were performed as described in Requena et al. 2009 
and Parra et al. 2008 (Parra et al., 2008, Requena et al., 2009).  P3 preps were re-suspended in 10 
mM HEPES, 0.5 mM EGTA, 0.1 mM magnesium chloride, 200 mM sucrose, pH 7.4.  Uptake 
buffer consisted of 20 mM HEPES, 100 mM potassium tartrate, pH 7.4 with the addition of 2.5 
mM magnesium sulfate and 2 mM ATP.  Nonspecific uptake was determined using 100 μM 
reserpine, a potent VMAT1 and VMAT2 inhibitor.  Since PC12 cells also contain VMAT1, 
VMAT2-specific uptake was determined using 1 μM tetrabenazine (TBZ), a VMAT2-specific 
inhibitor (Erickson et al., 1996, Holtje et al., 2000).  Uptake buffer and 200 μg vesicular prep 
were incubated at 30°C for 10 minutes.  0.1 μM [3H]-serotonin (Perkin Elmer, catalog 
#NET4980) was added and samples were incubated at 30°C for 6 minutes.  Background was 
determined under the same conditions, except without the addition of vesicular prep.  Uptake 
was terminated by the addition of cold buffer (20 mM HEPES, 100 mM potassium tartrate, pH 
7.4) and filtered through 0.2 μm filter paper (PALL supor 200, catalog #60305) that had been 
soaked in 0.3% polyethleneimine for at least 30 minutes.  Filter paper was washed with cold 
uptake buffer and [3H]-serotonin on the filter paper was determined using a scintillation counter.  
Background values were subtracted from total uptake and uptake with reserpine or TBZ.  Uptake 
with reserpine or TBZ are graphed as percentage of total uptake. 
2.2.10 MTS Assay 
To determine cytotoxicity of drugs utilized, a colorimetric MTS assay was used according to 
manufacturer’s instructions (Abcam).  10-15 x 103 cells were plated in poly-D-lysine coated 96 
well plates and treated up to 18 hours with the aforementioned drug concentrations or the 
appropriate DMSO vehicle percentage.  Following drug treatment, the MTS solution was added 
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and cells were incubated for 30 minutes at 37°C.  After brief shaking, absorbance was read on a 
plate reader at 490 nm.  Data from drug treated cells were calculated as percentage of vehicle for 
analysis.  For comparison, drug treatments at later times were compared to drug treatment time at 
1 hour, as no true ‘0 hour’ timepoint existed due to the 30 minute incubation time with MTS. 
2.2.11 Statistics 
Western blot bands were quantified using ImageJ (NIH, Bethesda, MD).  VMAT2-GFP density 
values were normalized to tubulin density values prior to further analysis.  All graphs were 
plotted and statistics performed on GraphPad Prism (GraphPad Software, La Jolla, CA, 
www.graphpad.com).  Most graphed data are represented as mean +/- SEM or as individual 
points with the mean indicated.  Unless otherwise indicated, data were analyzed using Kruskal-
Wallis non-parametric ANOVAs and Dunn’s multiple comparison post-hoc tests.  Data from 
time-lapse live imaging experiments were analyzed using repeated measures ANOVAs, as well 
as Dunnett’s multiple comparison post-hoc tests.  An unpaired two-tailed t-test was used to 
analyze co-localization data. 
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3.0  RESULTS 
3.1 DETERMINATION OF VMAT2 HALF-LIFE 
To begin to understand VMAT2 degradation mechanisms, I first examined the half-life of the 
transporter. To my knowledge, nothing has been published concerning the half-life of VMAT2.  
Because VMAT2 is a glycosylated, 12 transmembrane domain transporter, it is assumed to be a 
very stable protein and the half-life is expected to be quite long.  50 µg/mL of cycloheximide, a 
protein synthesis inhibitor, was used to determine VMAT2 half-life when transiently over-
expressed in PC12 cells (Anwar et al., 2011).  As demonstrated in Figure 9, the mature form of 
VMAT2 levels decreased with increasing cycloheximide treatment time, reaching approximately 
50% of control (0 hours incubation) by 12 hours incubation.  However, this is a relatively long 
cycloheximide treatment time, as cycloheximide is very toxic at long incubation times.  Indeed, I 
observed reduced protein content at later time points, indicating cell death.  Treatment of cells 
with a reduced concentration of cycloheximide, 10 μg/mL, also resulted in significant cell death 
at longer incubation times.  These observations lead me to believe that the cycloheximide 
method is a crude estimation of VMAT2 half-life, complicated by compromised cell functioning. 
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Figure 9.  VMAT2 half-life following cycloheximide.  PC12 cells transfected with VMAT2-GFP 
were incubated with 50 μg/mL cycloheximide to inhibit protein synthesis.  Cells were lysed at the 
indicated times and subjected to immunoblotting.  (A) Membranes were probed with anti-GFP and 
anti-tubulin.  (B) Mature VMAT2-GFP was quantified using ImageJ and normalized to tubulin 
levels.  Data from 3 independent experiments are expressed as mean +/- SEM.  
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Due to the limitations of using cycloheximide for longer periods of time, a pulse-chase 
method was then used to determine VMAT2 half-life in PC12 cells stably expressing VMAT2-
GFP.  Results from the cycloheximide experiments and previous data concerning other 
transmembrane proteins indicate that VMAT2 turnover is likely relatively slow.  Because of this, 
cells were ‘pulsed’ for a long period of time with radiolabeled cysteine/methionine (24 hours) in 
order to maximize the radiolabeled mature VMAT2 that would be synthesized during that time 
period.  Cells were then ‘chased’ for an even longer period of time—up to 48 hours.  Using this 
method, the half-life of mature VMAT2 is approximately 35 hours, as shown in Figure 10.  
There is discrepancy between the VMAT2 half-life value using the cycloheximide method or the 
pulse-chase method.  However, the value obtained using the pulse-chase method more closely 
resembles what has been previously reported for plasma membrane transporters; to my 
knowledge the half-life for synaptic vesicular transporters has not been reported (Chu and Doyle, 
1985, Vicentic et al., 1999, Kimmel et al., 2001).  Furthermore, the pulse-chase methodology 
does not result in massive cell death, while long cycloheximide incubations do, yielding results 
less able to interpret.  It should be noted that this is an estimation of VMAT2 in an 
overexpression cell model system; in vivo estimations for endogenous protein could be quite 
different. 
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Figure 10.  VMAT2 half-life according to the pulse-chase method.  PC12 cells stably expressing 
VMAT2-GFP were ‘pulsed’ with radiolabeled methionine/cysteine for 24 hours, then ‘chased’ for 
up to 48 hours.  Samples underwent SDS-PAGE and autoradiography for detection of radiolabeled 
VMAT2. Mature VMAT2 was quantified using ImageJ.  Data from 3 independent experiments are 
expressed as mean +/- SEM. 
3.2 EFFECT OF PROTEASOME OR LYSOSOME INHIBITION ON VMAT2 
3.2.1 VMAT2 levels 
The goal of this project was to investigate mechanisms by which mature VMAT2 is degraded.  
Although synaptic vesicular proteins are traditionally thought to be degraded by the lysosome, 
few researchers have sought to examine the degradation of specific synaptic vesicular proteins.  
To do this, I primarily utilized pharmacological tools available to inhibit the function of 
lysosomes or proteasomes.  To inhibit lysosomal activity, I used E64 plus AEBSF.  E64 is an 
inhibitor of lysosome-specific cysteine-type cathepsin proteases (Barrett et al., 1982, Ahlberg et 
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al., 1985).  Since other types of proteases are in lysosomes, I also used AEBSF, a common serine 
protease inhibitor (Kollmann et al., 2009).  While AEBSF has been reported to affect the trypsin-
like catalytic site of the 26S proteasome, it does not affect the size of degradation products, 
suggesting its impact on overall proteasomal function is minimal (Kisselev et al., 1999).  Other 
lysosomal inhibitors that disrupt the acidic pH of the lysosome are more commonly used and 
more effective but were not used here as they could also inadvertently disrupt vesicular pH 
gradients required for normal VMAT2 function (Ahlberg et al., 1985, Wilcox and Mason, 1992).  
To inhibit the proteasome, I primarily used the more common MG132, a peptide aldehyde that 
reversibly inhibits the chymotrypsin-like site of the 26S proteasome (Rock et al., 1994, Lee and 
Goldberg, 1996, Kisselev et al., 2012).  Epoxomicin, a more specific inhibitor, was also used to 
confirm findings obtained with MG132 treatment.  Epoxomicin is an epoxyketone that 
irreversibly binds to the β subunits in the 20S proteasome core, effectively inhibiting all three 
major catalytic sites (Meng et al., 1999, Sin et al., 1999, Kisselev et al., 2012). 
PC12 cells stably expressing VMAT2-GFP were treated with 25 μM E64 and 200 μM 
AEBSF for up to 18 hours.  I then lysed the cells and ran equal amounts of proteins for western 
blotting.  Membranes were probed with anti-GFP to detect VMAT2 and anti-tubulin (Figure 11A 
is a representative blot).  As shown in Figure 11, at no point during the observed treatment time 
did lysosomal inhibition significantly affect mature or immature VMAT2 levels.  As a control 
for E64 effectiveness, blots were also probed with anti-ubiquitin (clone PD41).  As seen in 
Figure 12, higher molecular weight (above 100 kD) polyubiquitinated proteins accumulated after 
E64 treatment for 12 and 18 hours (non-parametric ANOVA p=0.0198; Dunn’s post-hoc test 
p<0.05 for 12 vs 0 hours and 18 vs 0 hours).  These data suggest E64 is entering the cells and 
having an overall effect, although not on VMAT2 under these conditions. 
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Figure 11.  VMAT2 does not accumulate following lysosomal inhibition.  PC12 cells stably expressing VMAT2-
GFP were incubated with 25 μM E64 and 200 μM AEBSF to inhibit lysosomal function.  Cells were lysed at the 
indicated times and subjected to immunoblotting.  (A) Membranes were probed with anti-GFP and anti-tubulin.  
Mature (B) and immature (C) VMAT2 was quantified using ImageJ.  Individual points with the mean indicated are 
plotted from 5 independent experiments. 
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Figure 12.  Polyubiquitinated proteins accumulate after lysosomal inhibition.  PC12 cells stably expressing 
VMAT2-GFP were incubated with 25 μM E64 to inhibit lysosomal function.  Cells were lysed at the indicated times 
and subjected to immunoblotting.  (A) Membranes were probed with anti-ubiquitin and anti-tubulin.  (B) 
Polyubiquitinated proteins above 100 kD were quantified using ImageJ.  Individual points with the mean indicated 
are plotted from 5 independent experiments.* indicates statistical significant difference from the 0 time point. 
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PC12 cells stably expressing VMAT2-GFP were similarly treated with 10 μM MG132.  
In contrast to results obtained with E64/AEBSF, MG132 treatment resulted in accumulation of 
mature VMAT2, shown in Figure 13.  Inhibition of the proteasome also resulted in an even 
greater accumulation of the immature form of VMAT2.  Interestingly, mature VMAT2 began to 
accumulate at an earlier incubation time than immature VMAT2.  Although there was a trend at 
earlier time points, immature VMAT2 did not significantly increase compared to the 0 time point 
until 6, 12 and 18 hours of MG132 incubation (non-parametric ANOVA p<0.0001; Dunn’s post-
hoc test p<0.05 for 6 vs 0 hours, 12 vs 0 hours and 18 vs 0 hours).  Mature VMAT2 did not 
significantly increase compared to the 0 time point until 12 and 18 hours of MG132 incubation 
(non-parametric ANOVA p=0.0332; Dunn’s post-hoc test p<0.05 for 12 vs 0 hours and 18 vs 0 
hours).  
To confirm these results, cells were also treated with 250 nM epoxomicin, a more 
specific proteasome inhibitor.  Peptide aldehydes, but not, to my knowledge, epoxomicin, have 
been reported to inhibit calpains and cysteine proteases (Sasaki et al., 1990, Rock et al., 1994, 
Tsubuki et al., 1996).  As shown in Figure 14, both mature and immature forms of VMAT2 
accumulated following incubation, confirming results observed following MG132 treatment.  
However, the changes in both mature and immature VMAT2 did not reach statistical 
significance.  The changes are more a trend and likely require increased sample size to reach 
statistical significance, although I am interpreting these results as indication of biological 
significance. 
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Figure 13.  Mature and immature VMAT2 accumulate following proteasomal inhibition with MG132.  PC12 cells 
stably expressing VMAT2-GFP were incubated with 10 μM MG132 to inhibit proteasome function.  Cells were 
lysed at the indicated times and subjected to immunoblotting.  (A) Membranes were probed with anti-GFP and anti-
tubulin.  Mature (B) and immature (C) VMAT2 was quantified using ImageJ.  Individual points with the mean 
indicated are plotted from 5 independent experiments.  * indicates statistical significant difference from the 0 time 
point.    
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Figure 14.  Mature and immature VMAT2 accumulate following proteasomal inhibition with epoxomicin.  PC12 
cells stably expressing VMAT2-GFP were incubated with 250 nM epoxomicin, a more selective proteasome 
inhibitor.  Cells were lysed at the indicated times and subjected to immunoblotting.  (A) Membranes were probed 
with anti-GFP and anti-tubulin.  Mature (B) and immature (C) VMAT2 was quantified using ImageJ.  Individual 
points with the mean indicated are plotted from 3 independent experiments. 
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Since the process of ERAD depends on proteasomal function, inhibiting the actions of 
proteasomes also ultimately inhibits the process of ERAD.  To determine if the effects on mature 
VMAT2 following MG132 or epoxomicin treatment were due solely to ERAD inhibition, cells 
were treated with 10 μM eeyarestatin I, an inhibitor of p97 (and perhaps Sec61) that’s 
specifically targeted to the ER, effectively preventing retrotranslocation (Wang et al., 2008, 
Cross et al., 2009, Wang et al., 2010).  While immature VMAT2 accumulated following 
eeyarestatin I, mature VMAT2 did not (shown in Figure 15; non-parametric ANOVA for 
immature VMAT2 p<0.05, Dunn’s post-hoc test p<0.05 for 18 vs 0 hours).  In fact, there is a 
trend toward a reduction in mature VMAT2-GFP, although this was not statistically significant.  
These data indicate that accumulation of the mature form of VMAT2 after MG132 or 
epoxomicin is not due to ERAD inhibition whereas the accumulation of immature VMAT2 
following MG132 or epoxomicin treatment could be due to ERAD inhibition.  However, p97 has 
also been reported to be involved in ER to Golgi trafficking (Zhang et al., 1994, Roy et al., 
2000).  Therefore, these results may reflect inhibition of that process by eeyarestatin I and not 
eliminate the possibility of an effect of ERAD inhibition on mature VMAT2 accumulation 
following inhibition of the proteasome.  Dalal and co-authors have called into question the 
involvement of p97 in ER to Golgi trafficking, as results from dominant negative expression of 
mutant p97 did not support this claim (Dalal et al., 2004).  However, the authors observed the 
formation of ER vacuoles following induction of the dominant negative mutant p97, which could 
then impact not only ER function, but ER to Golgi trafficking.  These results could be clarified 
utilizing a specific ERAD inhibitor that does not directly impact trafficking in the secretory 
pathway. 
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Figure 15.  Immature VMAT2 accumulates following ERAD inhibition.  PC12 cells stably expressing VMAT2-
GFP were incubated with 10 μM eeyarestatin I, an ERAD inhibitor.  Cells were lysed at the indicated times and 
subjected to immunoblotting.  (A) Membranes were probed with anti-GFP and anti-tubulin.  Mature (B) and 
immature (C) VMAT2 was quantified using ImageJ.  Individual points with the mean indicated are plotted from 3 
independent experiments * indicates statistical significant difference from the 0 time point.    
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Based on the estimated VMAT2 half-life reported here and other reports of long half-life 
for most transporters, there’s reason to believe the turnover time for VMAT2 is fairly long.  
Because of this, I used relatively long drug incubation times.  Inhibiting degradation systems, 
especially inhibiting proteasomal function, has deleterious consequences on overall cell 
functioning (Lam and Cadenas, 2008, Wang et al., 2015a).  MTS Assays were performed to 
address the degree of compromised cellular functioning during drug treatments.  While there was 
a slight decrease in cellular viability over time for most drug treatments, as shown in Figure 16, 
there was not massive cell death at the indicated drug times and concentrations.  Data are 
represented as percentage of DMSO vehicle control, taking into account any reduction in cell 
viability due to the presence of DMSO, although DMSO itself did not result in significant loss of 
cell viability (data not shown).    There was a statistically significant reduction in cellular 
function 25 µM E64/200 µM AEBSF treatment after 12 hours of drug treatment (non-parametric 
ANOVA p=0.0736,  Dunn’s post-hoc test p<0.05 for 12 hours vs 1 hour treatment time).  
Although not reaching statistical significance, there is a consistent observed reduction in cell 
function following 10 µM MG132 and epoxomicin treatment.  These data suggest that caution 
should be used in interpreting data from long incubation times of compounds inhibiting both the 
proteasome and lysosome, as cellular function is compromised.  However, with any drug 
treatment, cell function was not reduced more than 15%, indicating massive cell death was not 
occurring. 
 67 
 
Figure 16.  Cell viability following drug treatments.  PC12 cells stably expressing VMAT2-GFP were incubated 
with the indicated drugs for up to 18 hours.  Cell viability was assessed using a colorimetric MTS assay.  Data 
expressed as mean +/- SEM are represented as percentage of DMSO vehicle and are from 4 independent 
experiments.  * indicates significant difference from the 1 hour time point.    
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3.2.2 VMAT2 half-life 
Data collected from whole cell lysate is the product of a sum of multiple processes.  Hence, total 
VMAT2 levels following inhibition of degradation are a product of both degradation and 
synthesis.  To more directly examine VMAT2 degradation, I again employed the pulse-chase 
assay.  To measure the effect of inhibiting lysosomal function on VMAT2 half-life, PC12 cells 
stably expressing VMAT2-GFP were ‘pulsed’ for 24 hours, and ‘chased’ for long periods of 
time—up to 48 hours.  During the chase period, cells were treated with DMSO vehicle or 25 μM 
E64 and 200 μM AEBSF.  As seen in Figure 17, inhibition of lysosomal function did not affect 
the degradation rate or half-life of VMAT2.  These data strongly indicate that under basal 
conditions, VMAT2 degradation is unaffected by lysosomal inhibition. 
Due to the cumulative toxic effects of MG132 over long treatment times, it was not 
feasible to repeat this experiment while inhibiting the proteasome.  In lieu of this, pulse-chase 
assays were performed with a shorter, 1 hour ‘pulse’ time and shorter ‘chase’ times, up to 8 
hours.  Under these circumstances, MG132 had no effect on the half-life of mature VMAT2.  
There was a trend toward MG132 treatment increasing the half-life of immature VMAT2.  As 
before, control western blots were also performed on lysate and immunoprecipitation samples 
from the pulse-chase assays.  Upon further investigation, as seen in Figure 18E, MG132 seems to 
affect the degree of VMAT2 immunoprecipitation.  While more immature VMAT2 was 
immunoprecipitated following MG132 treatment, less mature VMAT2 was immunoprecipitated.  
This may indicate that inhibiting the proteasome may result in accumulation of modified mature 
VMAT2 that interferes with antibody-protein binding.  Importantly, the levels of 
immunoprecipitated VMAT2 were unaffected by lysosomal inhibition, indicating E64/AEBSF 
treatment  did  not  interfere  with  antibody-protein  binding  (refer to Figure 17E).   A variety of  
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Figure 17.  VMAT2 half-life following lysosomal inhibition.  PC12 cells stably expressing VMAT2-GFP were 
‘pulsed’ with radiolabeled methionine/cysteine for 24 hours, then ‘chased’ for up to 48 hours with DMSO vehicle or 
25 μM E64 and 200 μM AEBSF.  (A) Samples underwent SDS-PAGE and autoradiography for detection of 
radiolabeled VMAT2. Mature (B) and immature (C) VMAT2 was quantified using ImageJ.  Data from 3 
independent experiments are expressed as mean +/- SEM.  Control immunoblots were ran to determine VMAT2 
levels in lysate (D) and to evaluate consistency of the immunoprecipitation (E). 
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Figure 18.  VMAT2 half-life following proteasomal inhibition.  PC12 cells stably expressing VMAT2-GFP were 
‘pulsed’ with radiolabeled methionine/cysteine for 1 hour, then ‘chased’ for up to 8 hours with DMSO vehicle or 5 
μM MG132.  (A) Samples underwent SDS-PAGE and autoradiography for detection of radiolabeled VMAT2. 
Mature (B) and immature (C) VMAT2 was quantified using ImageJ.  Data from 3 independent experiments are 
expressed as mean +/- SEM.  Control immunoblots were ran to determine VMAT2 levels in lysate (D) and to 
evaluate consistency of the immunoprecipitation (E).  Note the inconsistent immunoprecipitation of VMAT2 
following MG132 treatment compared to vehicle treatment.  
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methods were utilized to equalize the immunoprecipitation of VMAT2 following MG132 
treatment, but were unsuccessful.  Unfortunately, this issue renders the interpretation of the 
pulse-chase data difficult, as a reduction in radiolabeled VMAT2 may reflect a reduction in 
immunoprecipitated VMAT2 from the sample and not an accurate representation of reduced 
VMAT2. 
3.2.3  VMAT2 cellular localization 
The data obtained here strongly suggests VMAT2 accumulates following proteasomal, but not 
lysosomal inhibition.  To confirm this and further assess the impacts of proteasomal and 
lysosomal inhibition on VMAT2 cellular localization, microscopy was used.  Time-lapse multi-
point microscopy was performed to visualize cells over time after being treated with MG132 or 
E64.  PC12 cells stably expressing VMAT2-GFP were differentiated with nerve growth factor 
(NGF) for 3-5 days, until the cells began to develop a more neuronal morphology (protruding 
extensions that make connections with the extensions of other cells).  Cells were then imaged for 
up to 10 hours following addition of DMSO vehicle, 5 µM MG132, or 25 µM E64/200 µM 
AEBSF.  Sampling was performed every 30 minutes at multiple points within a dish.  Figure 19 
displays example images taken for each drug treatment at 0, 3, 6, and 9 hours.  Overall, drug 
treatments caused many cells to retract their processes and ‘ball up’ or shrink—features 
characteristic of PC12 cells when insulted (Walkinshaw and Waters, 1994, Ivins et al., 1999).  
This was especially true following E64/AEBSF treatment, when many cells retracted processes, 
clumped together, and eventually perished.  A subset of cells also appeared to display a collapse 
of the nucleus, indicating the function of these cells was severely compromised, sometimes 
followed by cell death.  Although the nucleus was not labeled in these experiments, it is assumed 
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to be the circular area located in the PC12 cell soma devoid of VMAT2-GFP.  The area 
immediately surrounding this VMAT2-GFP void has slightly increased levels of VMAT2-GFP 
and is assumed to be the ER and Golgi region; a clear example is shown in the “Vehicle” panel 
of Figure 18.  Confirmation of these cellular locations could be confirmed with nucleus and ER 
markers used in live imaging studies.  Likewise, definitive identity of the plasma membrane (to 
assess cell size) could also be determined using such tools.  Analysis of fluorescent intensity of 
VMAT2-GFP revealed a significant, although subtle, increase in GFP intensity beginning at 7 
hours following addition of MG132 (Figure 20, repeated measures ANOVA p<0.0001, 
Dunnett’s post-hoc test p<0.05 for 7, 8, 9, and 10 hours treatment vs. 0 hour time point).  This 
increase was not observed following addition of DMSO vehicle.  The increase in VMAT2-GFP 
corroborates the increased VMAT2 protein levels following MG132 treatment seen in cell lysate.  
While there was a statistically significant overall effect of E64 treatment (repeated measures 
ANOVA p=0.01), post-hoc analysis did not yield significant differences between any treatment 
time point and the 0 hour time point, perhaps because of a low number of cells analyzed.  
VMAT2-GFP distribution across the soma was also analyzed following these drug treatments.  
As shown in Figure 21, MG132 treatment caused an accumulation of VMAT2-GFP near the 
nucleus, likely in or near the ER.  Note the reduced size of what is assumed to be the nucleus 
(located around 10 microns) following MG132 or E64/AEBSF treatment, indicating collapse of 
the nucleus, caused by the toxic effects of these compounds. 
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Figure 19.  Time-lapse live cell imaging following proteasomal or lysosomal inhibition.  PC12 cells were 
differentiated with NGF and treated for up to 10 hours with DMSO vehicle, 5 μM MG132, or 25 μM E64/200 μM 
AEBSF.  During this time, z stacks were obtained every 30 minutes.  Displayed here are example images from 0, 3, 
6, or 9 hours drug treatment. 
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Figure 20.  Proteasomal inhibition increases VMAT2-GFP levels during time-lapse live imaging.  PC12 cells were 
differentiated with NGF and treated for up to 10 hours with (A) DMSO vehicle, (B) 5 μM MG132, or (C) 25 μM 
E64/200 μM AEBSF.  Mean GFP fluorescent intensity was measured at each hour and plotted as mean +/- SEM.  * 
indicates p<0.05 as compared to the 0 time point.  For DMSO, MG132, and E64 treatment, the number of cells 
analyzed were 27, 57, and 10, respectively. 
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Figure 21.  VMAT2-GFP distribution across the soma after 6 hours drug treatment. PC12 cells underwent live cell 
imaging after being treated with DMSO vehicle, 5 μM MG132, or 25 μM E64/200 μM AEBSF.  Graphs are average 
GFP intensity across somas after 6 hours treatment.  VMAT2-GFP intensity is increased and proximity to the 
nucleus is closer after MG132 treatment.  The nucleus is around the 10 micron distance marker in all groups.  Data 
are represented as mean (n=12 cells per treatment group).  Example images are shown with yellow lines indicating 
where analysis was performed. 
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According to my previous data, immature VMAT2 accumulates to a great extent 
following proteasomal inhibition.  It is probable that this accumulation is due to the inhibition of 
ERAD, resulting in the build-up of VMAT2 located at the level of the ER.  To further confirm 
this, co-localization analysis was performed between VMAT2-GFP and PDI, an endoplasmic 
reticulum (ER) marker.  PC12 cells stably expressing VMAT2-GFP were differentiated for 3 
days with NGF, until cells displayed neurite-like extensions.  Cells were then treated for 6 hours 
with 5 µM MG132 or DMSO vehicle, fixed, and stained to label VMAT2-GFP and PDI.  
Confocal images, shown in Figure 22, were obtained and co-localization analysis was performed 
to determine Manders Coefficient—the fraction of VMAT2-GFP that overlaps with PDI 
(Manders et al., 1993, Dunn et al., 2011).  Following MG132 treatment, Manders Coefficient 
was increased, indicating more VMAT2 is co-localized with the ER following MG132 (t-test, 
p<0.0001).   Although the resolution using the method is not high enough to definitively state 
that PDI and VMAT2 co-localize, this data indicates that immature VMAT2 is accumulating, 
likely at the ER, after proteasomal inhibition. 
Similar co-localization experiments were attempted with VMAT2-GFP and LAMP1, a 
lysosomal marker, following E64/AEBSF treatment.  Cells were treated for 24 hours with 
DMSO vehicle or 25 µM E64/200 µM AEBSF, fixed, and stained for GFP and LAMP1.  
Unfortunately, as demonstrated in Appendix B, LAMP1 labeling was quite extensive and 
appears to be nonspecific, including staining throughout the nucleus, yielding results difficult to 
interpret.  Two different LAMP1 antibodies were used, both displaying similar degrees of non-
specificity.  A third LAMP1 antibody (Abcam, catalog #ab25630) and a LAMP2 antibody 
(Novus catalog #NB300-591) were also attempted, although neither resulted in a strong signal 
over background. 
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Figure 22.  Proteasomal inhibition increases fraction of VMAT2 localized to the ER.  PC12 cells were differentiated 
with NGF and treated for 6 hours with DMSO vehicle or 5 μM MG132.  (A) Cells were stained for GFP (green), 
PDI (a marker of the endoplasmic reticulum, red), or Hoechst stain to label nuclei (blue).  (B) Manders coefficient 
was calculated to assess the fraction of VMAT2-GFP co-localized with PDI and plotted as mean +/- SEM.  * 
indicates p<0.05.  For vehicle and MG132 groups the number of cells analyzed were 22 and 33, respectively. 
 
 
 
 
 
 
  
 78 
3.3 VMAT2 UBIQUITINATION 
Ubiquitination is a post-translational modification commonly associated with degradation.  
While primarily involved as a signal for degradation by the proteasome, ubiquitination can also 
be involved in trafficking or lysosomal degradation.  Because of these roles of ubiquitination, I 
became interested in investigating the potential involvement of this modification in VMAT2 
degradation.  From PC12 cell lysate (stably expressing VMAT2-GFP), VMAT2 was 
immunoprecipitated, samples subjected to immunoblotting, and membranes were probed with 
anti-ubiquitin.  Under basal conditions, I was unable to detect ubiquitinated VMAT2 under these 
circumstances.  There is no indication under what circumstances VMAT2 may be ubiquitinated 
and it is possible that the level of basal VMAT2 ubiquitination is quite low and beyond my 
detection capability using this method. 
To increase a potential signal, allowing for detection of VMAT2 ubiquitination, cells 
were treated for 12 hours with 10 μM MG132 or 25 μM E64 and 200 μM AEBSF.  
Immunoprecipitations and immunoblotting was performed as described and membranes were 
again probed with anti-ubiquitin.  As seen in Figure 23A, MG132, but not E64/AEBSF treatment 
resulted in the detection of ubiquitinated VMAT2.  As 12 hours is a fairly long incubation time, 
this experiment was repeated with 6 hours incubation time.  A slightly decreased, but still 
present, ubiquitinated VMAT2 was detected after proteasomal, but not lysosomal, inhibition as 
shown in Figure 23B.  These data indicated ubiquitinated VMAT2 accumulates following 
inhibition of the proteasome, but not lysosome. 
To further strengthen this hypothesis that ubiquitinated VMAT2 accumulates following 
inhibition of the proteasome, these experiments were repeated, probing membranes with K48-
specific  ubiquitin  or  K63-specific  ubiquitin  antibodies.   K48-linked  polyubiquitin  chains are 
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Figure 23.  Proteasomal inhibition increases ubiquitinated VMAT2.  PC12 cells stably expressing VMAT2-GFP 
were treated with DMSO vehicle, 25 μM E64/200 μM AMEBSF, or 10 μM MG132 for (A) 12 or (B) 6 hours.  
VMAT2 was immunoprecipitated from cell lysate using a VMAT2 antibody (C20, Santa Cruz) or goat IgG as a 
control.  Samples were subjected to immunoblotting and membranes were probed with anti-GFP to detect VMAT2-
GFP or anti-ubiquitin to detect ubiquitinated VMAT2. 
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Figure 24.  Proteasomal inhibition increases K48-linked polyubiquitinated VMAT2.  PC12 cells stably expressing 
VMAT2-GFP were treated with 10 μM MG132 or 25 μM E64/200 μM AMEBSF for 6 hours.  VMAT2 was 
immunoprecipitated from cell lysate using a VMAT2 antibody (C20, Santa Cruz) or goat IgG as a control.  Samples 
were subjected to immunoblotting and membranes were probed with (A) K48-linked polyubiquitin-specific or (B) 
K63-linked polyubiquitin-specific antibody. 
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typically associated with degradation by the proteasome (Thrower et al., 2000).  K63-linked 
polyubiquitin chains are usually associated with lysosomal degradation or acting as a trafficking 
signal (Geetha et al., 2005, Duncan et al., 2006, Lauwers et al., 2009, Huang et al., 2013b).  As 
demonstrated in Figure 24, K48-specific ubiquitin antibody, but not K63-specific ubiquitin 
antibody detected ubiquitinated VMAT2 following 6 hours of MG132 treatment.  Following 6 
hours of E64/AEBSF treatment, the K48-specific ubiquitin antibody very weakly detected 
ubiquitinated VMAT2, while the K63-specific ubiquitin antibody did not detect any 
ubiquitinated VMAT2.  These data indicate that ubiquitinated VMAT2 may be destined for the 
proteasome to undergo degradation. 
3.4  POTENTIAL ROLE OF PARKIN IN VMAT2 DEGRADATION 
The results obtained in this project suggest VMAT2 can be degraded by the proteasome.  
Degradation by the proteasome is often a specific process, dependent on multiple enzymes.  The 
E3 enzyme most often confers specificity, catalyzing the transfer of ubiquitin to the substrate.  
Because of this, I began looking into potential E3 ligases that are involved in VMAT2 
degradation.  Parkin, one such E3 ligase, has several putative substrates and is best known for its 
Parkinsonism-causing mutations.  The most clear role parkin has is in mitophagy, where it is part 
of a series of events inducing the degradation of damaged mitochondria (Geisler et al., 2010, Cai 
et al., 2012, Chen and Dorn, 2013).  Interestingly, parkin has been localized to synaptic vesicles, 
although its exact role there is unknown (Kubo et al., 2001, Mouatt-Prigent et al., 2004).  
Appropriate to its role in Parkinsonism, Drosophila expressing human mutant parkin exhibit 
degenerative dopaminergic cell loss.  This effect worsened when VMAT was knocked down and 
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was ameliorated when VMAT was over-expressed (Sang et al., 2007).  Although it was 
hypothesized that cytosolic dopamine contributes to mutant parkin-induced degeneration, the 
possibility that parkin, itself, affects VMAT was not ruled out. 
 We first found that purified GST-VMAT2 N terminus, and to a lesser extent GST-
VMAT2 C terminus, pulled down endogenous parkin from whole rat brain homogenate (Figure 
25).  Furthermore, VMAT2 co-immunoprecipitated parkin from PC12 cells over-expressing both 
proteins, as shown in Figure 26.  These data indicate that VMAT2 and parkin may interact and 
raise the tantalizing possibility that VMAT2 may be a parkin substrate. 
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Figure 25.  GST-VMAT2 fragments pull down parkin.  Purified GST alone, GST-VMAT2-N 
terminus, GST-VMAT2-cytoplasmic loop, or GST-VMAT2-C terminus were incubated with rat 
brain homogenate.  Samples underwent immunoblotting and membranes were stained with 
Ponceau or probed with parkin antibody.  The N terminus and to a lesser extent the C terminus of 
VMAT2 were able to pull down endogenous parkin. 
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Figure 26.  VMAT2 and parkin co-immunoprecipitate. VMAT2 was immunoprecipitated from 
PC12 cells over-expressing both VMAT2-GFP and parkin.  Western blot membranes were probed 
parkin and with GFP to assess immunoprecipitation of VMAT2.  Negative controls include 
VMAT2 antibody incubated with buffer in lieu of cell lysate and goat IgG instead of VMAT2 
antibody incubated with cell lysate. 
 
I then sought to determine if parkin was able to affect VMAT2 degradation.  While there 
was little indication parkin was altering VMAT2 directly, a series of articles were published 
midway through the project that could explain why.  Several groups have now demonstrated that 
parkin is in a constitutively autoinhibited conformation and requires phosphorylation of the 
serine 65 residue for activation (Wauer and Komander, 2013, Kazlauskaite et al., 2014, Koyano 
et al., 2014, Im and Chung, 2015).  The strategy was adjusted and I began to clone mutations that 
would result in constitutively active parkin.  Unfortunately, a series of technical challenges 
ensued, rending me unable to complete this undertaking.  A combination of poor transfection 
efficiency in PC12 cells and technical difficulties with subcloning kept this portion of the project 
at a standstill. 
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4.0  DISCUSSION 
4.1 SUMMARY OF RESULTS 
The purpose of this project was to investigate the mechanisms of VMAT2 degradation under 
basal conditions.  I used several techniques to evaluate VMAT2 levels, half-life, cellular 
localization, and ubiquitination when degradation machinery was inhibited.  In all cases, the data 
suggest that VMAT2 is degraded through the ubiquitin-proteasome pathway.  Although the 
primary interest was in the degradation of mature VMAT2, immature VMAT2 was also 
evaluated.  Inhibiting the proteasome and the process of ER-associated degradation resulted in an 
accumulation of immature VMAT2.  In addition to inhibiting ERAD, eeyarestatin I may also 
inhibit ER to Golgi trafficking as previously discussed, perhaps accounting for the accumulation 
of immature VMAT2.  However, VMAT2 co-localized more with the ER after proteasomal 
inhibition, again indicating that VMAT2 processing and folding in the ER is regulated by ER-
associated degradation.  While it is accepted that ERAD acts as a quality control mechanism for 
the majority of transmembrane proteins and these results are perhaps unsurprising, this is first 
time this process has been implicated for VMAT2.  
To follow up on the potential role of ERAD in VMAT2 quality control, one could now 
examine in further detail what specific machinery is involved.  To confirm the role of ERAD in 
VMAT2 quality assurance, it would be valid to then look further into what ERAD proteins are 
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involved in immature VMAT2 degradation.  Identification of VMAT2 binding partners would be 
a fine first step in this process.  Protein immunoprecipitation followed by mass spectrometry 
identification of binding partners remains a useful tool for such identification.  Genetic tools, 
such as RNA interference or CRISPR, could be used to knock-down proteins known to be 
involved in ERAD, such as EDEM1 or Hrd1, or any candidate proteins identified previously by 
mass spectrometry.  The effects on VMAT2 trafficking and function could then be assessed by 
confocal imaging and uptake assays.  ERAD is an important component of protein quality 
control; its dysfunction has deleterious consequences on the cell and presumably, VMAT2 
function.  In vitro, ERAD inhibition causes ER swelling and formation of vacuoles, impacting 
overall function (Dalal et al., 2004).  There is also some in vitro evidence indicating 
Huntington’s disease-causing mutant huntingtin adversely affects ERAD, perhaps contributing to 
disease pathology (Duennwald and Lindquist, 2008, Yang et al., 2010).  Mutations in p97/VCP, 
impacting ERAD, cause IBMPFD, inclusion body myopathy associated with Paget disease of 
bone and frontotemporal dementia, highlighting the importance of ERAD (Watts et al., 2004, 
Weihl et al., 2006).  In the PC12 cell model system used in this study, ERAD inhibition with 
Eeyarestatin I not only resulted in accumulation of immature VMAT2, but also resulted in a 
decrease (although statistically insignificant) of mature VMAT2.  While these results could be 
due to reduced ER to Golgi trafficking, they might also indicate that ERAD dysfunction could 
prevent maturation and further processing of VMAT2, affecting its overall function.   
Surprisingly, mature VMAT2 accumulated following proteasomal, but not lysosomal 
inhibition.  While other processes may account for this effect, these results imply that the mature 
form of VMAT2 may also be degraded by the proteasome.  However, there are alternative 
explanations for these results, which must be interpreted with care.  Inhibiting the proteasome 
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influences many cellular processes, which could, in turn affect VMAT2 levels.  For example, 
Longva and colleagues suggest that while the EGF receptor accumulates following proteasomal 
inhibition, it’s not likely the proteasome is a direct target of EGFR degradation (Longva et al., 
2002).  Rather, proteasomal inhibition could be affecting a factor that’s involved with EGFR 
trafficking or lysosome-mediated degradation.  Since I did not observe VMAT2 accumulation 
following lysosomal inhibition, this interpretation is unlikely.  What’s more likely is the 
alternative explanation that the accumulation of mature VMAT2 following proteasomal 
inhibition is an effect of increased synthesis, trafficking or processing of immature VMAT2.  
Proteasome inhibition can block degradation of transcription factors that normally limit 
transcription, thereby increasing total transcription of a protein (Lipford and Deshaies, 2003, 
Auld et al., 2006).  In this case, VMAT2 synthesis should be assessed by qPCR or a related 
technique under conditions of proteasomal inhibition to confirm or reject this interpretation.  
Inhibiting the proteasome also induces the heat shock response, which includes the upregulation 
of both cytosolic and ER molecular chaperones (Bush et al., 1997, Lee and Goldberg, 1998).  
These ER chaperones could promote folding and processing of proteins in the ER, possibly 
contributing to the accumulation of mature VMAT2.   
The accumulation of K48-linked polyubiquitinated VMAT2 also supports the hypothesis 
that VMAT2 is degraded in a proteasome-dependent manner, as K48-linked polyubiquitin chains 
are often associated with targeting for proteasomal degradation.  It is unclear using this method if 
the accumulated VMAT2 is the immature or mature form.  As the western blot expresses as a 
smear of high molecular weight ubiquitinated VMAT2, it is not possible to determine the exact 
form of the ubiquitinated VMAT2 without further experimentation.  This smear, seen frequently 
in the literature, is probably the result of slower migration due to glycosylation and multiple 
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ubiquitination states.  These data demonstrating the accumulation of K48 polyubiquitinated 
VMAT2 don’t exclude the possible involvement of other polyubiquitin chains or 
monoubiquitination.  Only K48-linked and K63-linked chains were investigated, as these are the 
most common.  Certainly polyubiquitination and monoubiquitination aren’t mutually exclusive; 
VMAT2 is likely capable of having multiple ubiquitination states, depending on the 
circumstance.  Subcellular fractionation to isolate compartments and separate mature from 
immature VMAT2 could be used in conjunction with mass spectrometry to more definitively 
identify ubiquitin chain types conjugated to each form of VMAT2.  Similar techniques, as well 
as the utilization of single point mutations could also be used to identify potential residues that 
are ubiquitinated.   
The accumulation of polyubiquitinated VMAT2 following MG132 treatment implies, but 
does not show definitive proof of proteasomal degradation.  Ubiquitination is involved in several 
cellular processes, not just degradation.  For instance, ubiquitination could be an internalization 
signal for endocytosis, as has been suggested for numerous transporters and receptors (Geetha et 
al., 2005, Miranda et al., 2007, Eden et al., 2012).  When VMAT2 ubiquitination residues are 
identified, as suggested in the previous paragraph, they could then be mutated and the 
localization and function of VMAT2 assessed.  It is unclear if VMAT2 degradation is a specific, 
regulated process.  If so, perhaps a particular VMAT2 residue is vital for the ubiquitination.  
Perhaps specific enzymes (namely, E3 enzymes) play a role in VMAT2 degradation.  
Identification of an E3 enzyme that regulates VMAT2 degradation would provide an avenue of 
VMAT2 regulation that has remained a black box. 
Despite the traditional belief that transmembrane proteins are primarily degraded through 
the endo-lysosomal pathway, there was little evidence suggesting lysosomal inhibition affected 
 88 
VMAT2.  There could be several reasons for this surprising result.  Others have suggested E64 
has relatively poor penetration into cells (Wilcox and Mason, 1992).  However, as others have 
also demonstrated, polyubiquitinated proteins accumulated following E64 incubation, indicating 
E64 was entering cells and being effective (Qiao and Zhang, 2009).  As E64 is only inhibiting a 
subset of proteases located in lysosomes, it’s possible that other, non-inhibited proteases are 
responsible for VMAT2 degradation.  While other compounds are more effective at completely 
blocking lysosomal degradation, they do so by altering the acidic environment within the 
organelle, often by disrupting the pH gradient (Ahlberg et al., 1985).  Using these compounds is 
not entirely feasible, as they may then disrupt the pH gradient of vesicles, perhaps interfering 
with VMAT2 in a way independent of degradation.  These experiments would yield results 
equally difficult to interpret. 
It is also possible that VMAT2 degradation is lysosome-dependent under specific 
circumstances.  This project focused mainly on degradation under basal conditions, or 
degradation as a means of regulating VMAT2.  As with many receptors and transporters, is it 
possible that lysosomal-mediated VMAT2 degradation is activity-dependent.  That is, following 
exocytosis, VMAT2 is integrated within the plasma membrane to later undergo endocytosis and 
sorting (perhaps to the lysosome for degradation).  Under these conditions, synaptic activity 
would be a pre-requisite for VMAT2 degradation.  It would be straightforward to investigate this 
first in an in vitro cell model, then potentially in slice preparations.  For example, VMAT2 
levels, localization, and ubiquitination could be assessed following depolarization. 
These experiments were performed in a PC12 cell model system—lysosomal-mediated 
degradation of VMAT2 may play a more prominent role in neurons.  It is likely that VMAT2 is 
preferentially trafficked to dense core vesicles in PC12 cells (Yao et al., 2004).  It has been 
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proposed that these vesicles, like secretory granules, do not fully collapse with the plasma 
membrane and recycle locally, but ‘return’ to the trans-Golgi network (Kelly, 1993, Sulzer et al., 
2016).  Contrary to this, there is evidence that LDCVs in PC12 cells can undergo local recycling 
similar to synaptic vesicles, perhaps indicating a difference between LDCVs containing 
monoamines and DCVs containing peptides or hormones (Bauer et al., 2004a, Bauer et al., 
2004b). 
In addition to activity-induced degradation, another circumstance under which VMAT 
could be potentially degraded is following psychostimulant exposure.  There is substantial 
evidence that shortly (1 hour) after high doses of methamphetamine administration in vivo, 
VMAT2 levels and uptake activity are reduced (Brown et al., 2000, Eyerman and Yamamoto, 
2007, Chu et al., 2010).  It has been suggested that VMAT2 is trafficked out of the synaptic 
terminal or redistributed from a “cytoplasmic” fraction to a “membrane-bound” fraction (Riddle 
et al., 2002).  However, a satisfying explanation for this reduction or redistribution has not been 
found.  Intriguingly, co-current with this reduction in VMAT2 levels, there was increased 
VMAT nitrosylation (Eyerman and Yamamoto, 2007).  S-nitrosylation is a post-translational 
modification that has been shown to reduce VMAT2 uptake activity in vitro (Wang et al., 
2015b).  While the exact mechanisms nitrosylation exerts on VMAT2 is unknown, this 
modification has been implicated in the degradation of some proteins (Gow et al., 1996, Dunlop 
et al., 2002).  It is possible that VMAT2 is targeted for degradation following high 
methamphetamine doses.  Perhaps this reduction in VMAT2 levels further contribute to 
methamphetamine-induced loss of synaptic terminals, further increasing cytosolic dopamine 
levels after initially increasing them by inhibiting (or reversing) VMAT2.   
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Interestingly, preliminary data from our laboratory shows that administration of the 
potent psychostimulant methylenedioxypyrovalerone (MDPV) in rats results in a significant 
decrease of VMAT2 protein levels in the striatum (see Appendix C).  These results were 
recapitulated in PC12 cells expressing VMAT2 and the dopamine transporter.  Similar to results 
seem following methamphetamine administration, these findings may identify conditions for 
VMAT2 degradation and also validate our PC12 cell model to study VMAT2 degradation 
mechanisms.  While methamphetamine is thought to re-distribute dopamine from vesicles to the 
cytoplasm, it is unknown if the same is true of MDPV (Sulzer and Rayport, 1990, Sulzer et al., 
1995).  MDPV has been described as a dopamine transporter blocker; it has not been identified 
as a dopamine transporter substrate and its actions, if any, on VMAT2 or vesicles are unknown 
(Baumann et al., 2013, Anneken et al., 2015).  Pursuit of MDPV (and methamphetamine) 
mechanisms of action would be a logical and valuable avenue to follow, contributing to our 
knowledge of interplay between methamphetamine or MDPV and VMAT2. 
In summary, these data indicate that VMAT2 is degraded primarily by the proteasome 
under basal conditions.  Under these conditions, there is no evidence indicating VMAT2 is 
degraded in a lysosome-dependent manner.  Further experimentation is required to confirm these 
findings, as there are multiple interpretations and explanations for the data.  However, a model 
for VMAT2 degradation is emerging, suggesting the proteasome may play a larger role than 
initially thought.  Under the basal conditions tested in this study, VMAT2 degradation may be 
more dependent on the proteasome, as suggested in Figure 27.  Although not tested here, it is 
possible that VMAT2 degradation is lysosomal-dependent following periods of neuron activity, 
as suggested in Figure 28. The two degradation pathways are not mutually exclusive and 
VMAT2 degradation may very well rely on both. 
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Figure 27.  Model of proteasome-mediated VMAT2 degradation.  Under basal conditions (or unknown conditions), 
VMAT2 degradation may be mediated by the proteasome.  In a mechanism of fast and local degradation, VMAT2 
located in the presynaptic terminal could be ubiquitinated (1) and targeted for degradation by the proteasome (3).  
To do so, accessory proteins (so far, unidentified) would have to be involved in the retrotranslocation of VMAT2 
from the vesicular membrane (2). 
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Figure 28.  Model of lysosome-mediated VMAT2 degradation.  Following exocytosis (1), VMAT2 is internalized 
(possibly with ubiquitination acting as an internalization signal) in a clathrin-dependent manner (2) and either 
undergoes recycling for further use at the presynaptic terminal (3) or is sorted into early endosomes (4).  At this 
point, VMAT2 targeted for degradation would be further sorted into multivesicular bodies (5), which then undergo 
retrograde transportation back to the cell body for lysosomal degradation (6).  This pathway of VMAT2 degradation 
may be dependent on exocytosis and would be a slow process, as it requires retrograde transport to the cell body. 
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4.2 LIMITATIONS OF STUDY 
There are several limitations of this project and caveats to interpreting this data, some already 
discussed.  One has to be cautious when extrapolating information from a cell model system and 
making inferences about in vivo mechanisms.  Firstly, it is unclear if VMAT2 is trafficked and 
regulated in PC12 cells as it would be in neurons.  PC12 cells have been used considerably to 
evaluate catecholamine exocytosis and mechanisms of VMAT2 regulation (Schweitzer et al., 
1995, Kozminski et al., 1998, Holtje et al., 2000, Pothos et al., 2000).  Despite this, it is not 
known if PC12 cells contain the full complement of accessory proteins or processes that would 
regulate VMAT2 in neurons.  Additionally, PC12 cells contain endogenous VMAT1 and it is 
unclear if this would affect results when assessing exogenously added VMAT2 (Liu et al., 1994). 
 Caution should be taken when interpreting results from an over-expression system.  
Mechanisms of degradation that occur in an over-expression system may not be the same as 
occurs with an endogenous protein.  Furthermore, there was a GFP tag on the VMAT2 I utilized.  
GFP is a fairly large tag and could potentially interfere with ubiquitination sites or other binding 
sites (Yewdell et al., 2011).  Unfortunately, there are technical difficulties when investigating 
proteins like VMAT2, for which reliable antibodies are difficult to find, necessitating an over-
expression system using a GFP-tagged VMAT2.  Where possible, a neuronal cell model 
endogenously expressing VMAT2 should be used to replicate these results.  The majority of 
these experiments would be quite difficult to perform in primary dopamine neurons—a gold 
standard for in vitro cell models.  The low yield of dopaminergic neurons in most primary 
neuronal preparations provides technical challenges.  However, it would be useful to further 
explore the feasibility of these experiments in primary dopamine neurons, as these data, 
regardless of the results, would contribute useful information to the field. 
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Interpreting data from manipulations of degradation systems is complicated.  Inhibition 
of one system affects the others.  For example, there’s evidence that long (24 hours) inhibition of 
the lysosome also inhibits proteasomal function (Qiao and Zhang, 2009).  Ubiquitinated proteins 
accumulate when either lysosomal or proteasomal function are inhibited.  Unable to be degraded, 
these proteins remain ubiquitinated, thereby limiting free ubiquitin and indirectly inhibiting the 
other degradation process (Swaminathan et al., 1999).  However, proteasome inhibition has also 
been demonstrated to up-regulate autophagy, in part due to ER stress and the subsequent 
unfolded protein response (Rideout et al., 2004, Iwata et al., 2005, Ding et al., 2007, Pandey et 
al., 2007, Ding and Yin, 2008, Du et al., 2009).  Thought to be merely compensation, it may be 
that the interplay between the two systems is more complex (Korolchuk et al., 2010, Lilienbaum, 
2013).  For example, inhibition of autophagy also inhibits the UPS, although this may be an 
indirect effect.  Korolchuk and co-authors propose that autophagy inhibition results in the 
accumulation of p62, which competes with ubiquitin binding proteins that normally act to shuttle 
ubiquitinated proteins to the proteasome (Korolchuk et al., 2009a, Korolchuk et al., 2009b).  In 
this way, substrates are unable to get to the proteasome, resulting in an apparent decrease in 
proteasome activity.  Because of this interplay between degradation pathways, it is difficult to 
isolate results and attribute them to one system.  Inhibiting one system can cause a chain reaction 
that alters the entire homeostasis of the cell.  Inhibiting the proteasome affects numerous proteins 
and these proteins could, in turn, affect numerous other proteins.  Therefore, results from this 
study using proteasome and lysosome inhibitors may be indirect and due to alterations in other 
processes and/or compensatory mechanisms. 
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4.3 IMPLICATIONS FOR THE FIELD 
It has long been believed that post-ER degradation of plasma membrane and synaptic vesicular 
transmembrane proteins are primarily mediated by the lysosome, often through the endo-
lysosomal pathway, as shown in Figure 28.  This theory is logical, as it would require a relatively 
great amount of effort and appropriate assembly of accessory proteins to remove a glycosylated 
transmembrane protein from a membrane, allowing it to be degraded by the proteasome.  This 
basic fact has limited research on the possibility of proteasome-mediated degradation of mature 
transmembrane proteins post-ER and Golgi processing.  As previously stated, there exist only a 
few examples of post-ER retrotranslocation of transmembrane proteins, occurring in the Golgi 
and mitochondria (Stewart et al., 2011, Xu et al., 2011, Tong et al., 2014, Hwang et al., 2016).  
Although it seems unlikely that the cellular machinery required to do such a thing exists at the 
presynaptic terminal for plasma membrane or synaptic vesicular proteins, I urge the scientific 
community not to close themselves to the possibility.  As it stands, lysosomes have not been 
observed in the presynaptic terminals of dopamine neurons.  Therefore, the neuron must spend 
energy transporting transmembrane proteins back to the cell body for lysosomal degradation.  
Alternatively, the presynaptic terminal contains a number of proteasomes, which already play an 
important role in regulating various synaptic proteins.  Degradation mediated by the proteasome 
would provide a fast, local mechanism for regulation of pre-synaptic protein levels.  In contrast, 
degradation mediated by the lysosome can take days, as it requires retrograde transport back to 
the cell body. 
In addition to proteins normally thought to be involved in retrotranslocation (translocon 
pore, p97 or a related ATPase, etc.), there is another mechanism that may aid in the 
retrotranslocation of transmembrane proteins.  Intramembrane proteases are a group of proteases 
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that cut transmembrane proteins, facilitating the removal of a portion from the membrane 
(Sannerud and Annaert, 2009, Avci and Lemberg, 2015, Langosch et al., 2015).  Thought to be a 
specific, targeted process, these proteases are capable of cleaving proteins in a hydrophobic 
environment (Langosch et al., 2015).  There is evidence that they aid in the process of ERAD, 
but they also exist in a number of other places in the cell including the Golgi, endosomes, and 
plasma membrane (Friedmann et al., 2006, Boname et al., 2014, Avci and Lemberg, 2015).  The 
products of intramembrane protease cleavage sometimes act as signaling molecules, but can also 
initiate protein degradation (Alba et al., 2002, Kanehara et al., 2002, Avci and Lemberg, 2015).  
To my knowledge, intramembrane proteases have not been observed in synaptic vesicles.  While 
speculative, it is an interesting thought that if there, they could possibly aid in the fast removal of 
synaptic vesicular proteins.  This would be a way in which synaptic vesicular proteins could be 
regulated while still within the synaptic vesicle. 
The idea that VMAT2 would be degraded via the endo-lysosomal pathway relies on the 
full collapse of the vesicle into the plasma membrane during exocytosis, as it seen with 
traditional synaptic vesicles.  Although contested, there is indication that some vesicles undergo 
“kiss and run”, when they release a portion of their contents through a pore instead of fully 
collapsing (Zhang et al., 2007, Park et al., 2012).  In chromaffin cells, the release of DA through 
this mechanism has been observed (Fulop et al., 2005).  It’s unclear if this also occurs in 
dopaminergic neurons, although it’s been suggested as a mechanism of release for DCVs in 
PC12 cells as well, particularly relevant for this project (Omiatek et al., 2010).  It is also 
unknown if and when synaptic vesicles undergoing kiss and run recycle through the endosomal 
pathway and if so, how they are targeted for degradation.  In fact, there is much unknown in the 
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field regarding SV and DCV recycling and even less about the degradation of vesicular proteins.  
Any research regarding such topics would contribute knowledge to this field. 
The hypothesis that synaptic vesicular proteins, especially transporters, can be degraded 
in a specific manner is intriguing.  Targeted degradation of vesicular transporters would be a 
mechanism of regulation that would definitively reduce neurotransmission without relying on 
time-consuming transcriptional methods.  Post-translational modifications—including 
ubiquitination—are a relatively fast way to regulate protein activity.  Ubiquitination is most often 
immediately associated with degradation.  It’s becoming increasingly clear that it has other roles, 
including post-Golgi trafficking or acting as an internalization signal for plasma membrane 
proteins (Komander and Rape, 2012, Yuan et al., 2014, Swatek and Komander, 2016).  Its role in 
the regulation—beyond just degradation—of synaptic vesicular proteins, including VMAT2, 
should be further investigated. 
Another intriguing idea is that synaptic vesicles could themselves, as a whole, be 
degraded via autophagy, similar to mitophagy.  Parkin, with the aid of other proteins, targets 
damaged mitochondria for degradation by the autophagy system.  Parkin has also been observed 
at the membrane of synaptic vesicles; it isn’t known exactly why.  There is, however, recent 
evidence that autophagy may be involved with synaptic vesicle degradation.  Specifically, 
autophagy activation by rapamycin reduced the number of presynaptic vesicles and evoked 
dopamine release (Hernandez et al., 2012).   Interestingly, these effects were seen in slices not 
containing dopaminergic cell bodies.  As lysosomes are traditionally not thought to reside in 
presynaptic terminals, the results imply that autophagy could locally regulate synaptic vesicles 
without the action of lysosomes.  These data strongly indicate autophagy plays a role in synaptic 
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vesicle degradation; it would be worthwhile to further investigate this mechanism and any 
potential involvement of parkin. 
The involvement of the dopaminergic system in the etiology of several neurological 
disorders and diseases has made molecular components of this system attractive therapeutic 
targets.  VMAT2 is not excluded from this, and has been proposed as treatment in several 
instances.  Currently, TBZ, the VMAT2 inhibitor is approved for treatment of Huntington’s 
disease and chorea (Frank, 2010).  These movement disorders are characterized by excessive 
movement, thus VMAT2 inhibition is a logical avenue of treatment.  While VMAT inhibition 
has also been proposed as a treatment for psychostimulant abuse, support for this option is varied 
(Dwoskin and Crooks, 2002, Wilhelm et al., 2008).  Lobeline reduces amphetamine-induced 
dopamine output, suggesting it may then reduce the “rewarding” effect of psychostimulants that 
enhance dopamine release (Miller et al., 2001).  However, the side effects of VMAT inhibition 
can be quite severe, including depressive-like symptoms, subtle motor deficits, as well as 
peripheral effects in the gut.  Moreover, long-term inhibition of VMAT2 may be detrimental, as 
evidenced by increased vulnerability to toxic insults and degeneration in models of VMAT2 
knockdown or pharmacological inhibition.  
While there exists tools to reduce VMAT activity, there are none developed to increase 
VMAT activity.  Such a tool would be useful in diseases of monoaminergic depletion, such as 
Parkinson’s disease.  Targets to increase protein activity are more difficult to identify and so are 
uncommon therapies.  Inhibiting VMAT2 degradation to increase VMAT2 levels may be an 
attractive option for therapeutic development, but hinges on specificity.  It is unknown if the 
degradation of synaptic vesicle proteins can be individually modulated, or occurs en masse.  It is 
possible that at least under some circumstances, synaptic vesicle proteins are degraded using 
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pathways more suggestive of bulk degradation, such as autophagy.  Furthermore, the inhibition 
of ERAD or other protein quality control mechanisms should be avoided.  Inhibition of these 
processes would likely not be beneficial and may be counter-productive, reducing levels of 
mature and correctly folded VMAT2 that are ultimately trafficked to the vesicle.  Unfortunately, 
too little is known about VMAT2 regulation to even begin identifying viable activating options.  
Identifying in detail the molecular mechanisms of VMAT2 degradation could open up this door 
and provide viable therapeutic targets designed to increase VMAT2 levels and treat devastating 
diseases. 
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APPENDIX A 
VMAT UPTAKE IN PC12 CELLS OVER-EXPRESSING VMAT2-GFP 
Radiolabeled serotonin vesicular uptake assays were performed on crude vesicular preparations.  
Nonspecific uptake was measured by addition of 100 µM reserpine, a potent VMAT1 and 
VMAT2 inhibitor.  VMAT2 uptake was measured by addition of 1 µM TBZ, a VMAT2 
inhibitor.  Unexpectedly, the addition of reserpine or TBZ reduced uptake similarly, indicating 
that VMAT2 is contributing to nearly the entire measured uptake.  There are multiple 
explanations for this.  For one, the levels of VMAT1 are unknown in this model and it is possible 
that the over-expression of VMAT2 reduces them, or makes their contribution negligible.  The 
more likely explanation is that TBZ is also inhibiting VMAT1 at the concentration used.  
However, others have reported little or no effect of 1 µM TBZ on VMAT1 activity in PC12 and 
other cell lines (Erickson et al., 1996, Holtje et al., 2000).  At 1 µM, TBZ is unlikely to effect 
100% of VMAT1 activity, as it should affect 100% of VMAT2 activity, thereby leading me to 
conclude that the majority of measured vesicular uptake is VMAT2-mediated. 
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Figure 29.  Vesicular Uptake in PC12 Cells Stably Expressing VMAT2-GFP.  Radiolabeled 
serotonin uptake was measured in a crude vesicular preparation.  100 μM reserpine and 1 μM TBZ 
blocked a portion of total uptake, suggesting the VMAT2-GFP construct is functional.  Data 
represented as mean, reserpine and TBZ data represented as mean +/- SEM (n=4 independent 
experiments).  Non-parametric one-way ANOVA analysis resulted in p=0.0249 significant 
difference between groups. * indicates p<0.05 as compared to total uptake from Dunn’s post-hoc 
tests. 
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APPENDIX B 
LAMP1 NONSPECIFIC LABELING 
Cells were treated with DMSO vehicle of E64/AEBSF for 24 hours, a lengthy incubation in 
attempt to maximize any effect E64 may have on VMAT2.  Cells were then stained with two 
different LAMP1 antibodies.  Both LAMP1 antibodies displayed what appears to be nonspecific 
labeling.  LAMP1 is expected to label more discretely and display a punctate pattern.  Instead, 
LAMP1 labeling with these antibodies appears throughout the cell in a rather diffuse manner, 
suggesting a lack of specificity. 
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Figure 30.  LAMP1 Antibody non-specific staining.  PC12 cells were differentiated with NGF and treated for 24 
hours with DMSO vehicle or 25 μM E64/200 μM AEBSF.  Cells were stained for VMAT2-GFP (green), LAMP1 (a 
marker of endosomes and lysosomes, red), or Hoechst stain to label nuclei (blue).  (A) A rabbit polyclonal LAMP1 
antibody from Abcam was used and (B) a monoclonal antibody from the DSHB was also used.  Both antibodies 
appear to display nonspecific labeling. 
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APPENDIX C 
EFFECT OF MDPV ON VMAT2 
Rats were injected with 3 mg/kg MDPV and sacrificed 24 h later.  The striatum was dissected 
and VMAT2 levels were examined by western blot.  PC12 cells stably expressing VMAT2-GFP 
with or without transfected DAT (MDPV blocks DAT) were incubated with 1 µM MDPV for the 
indicated times and again, VMAT2 levels examined by western blot (Baumann et al., 2013, 
Anneken et al., 2015).  In both instances, MDPV administration reduced VMAT2 levels, 
suggesting a model for VMAT2 degradation.  Although preliminary, these result are promising 
and may provide a means of further investigating mechanisms of VMAT2 degradation. 
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Figure 31.  MDPV reduces striatal VMAT2 levels.  Rats were given 3 mg/kg MDPV (closed bar) 
or saline (open bar) and sacrificed 24 hours later.  VMAT2 levels were determined by western 
blots, quantified, and represented as mean + SEM (n=5).  MDPV administration significantly 
reduced VMAT2 levels, indicating increased VMAT2 degradation. 
 
 
 
Figure 32.  MDPV reduces VMAT2 levels in PC12 cells.  PC12 cells stably expressing VMAT2-GFP transfected 
with or without DAT were treated with 1 µM MDPV for the indicated times.  VMAT2 levels were determined by 
western blots.  VMAT2 levels decreased with increasing MDPV treatment time in cells also expressing DAT.  These 
results confirm observations in the previous figure and provide validation for a cell model examining VMAT2 
degradation.  
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